424 Rec'd PCT/PTO 26 MAY 2000

FORM-PTO-1390 (Rev. 5-93) U.S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER: 2369-1-002

U S. APPLICATION NO. (If known, see 37 C F R. 1.5): 09/555296

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/GB98/03530	26 November 1998	26 November 1997

TITLE OF INVENTION: HISTAMINE AND SEROTONIN BINDING MOLECULES

APPLICANT(S) FOR DO/EO/US: Patricia Ann Nuttall and Guido Christian Paesen

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. [X] This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. [ ] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. [X] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).
4. [X] A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. [X] is transmitted herewith (required only if not transmitted by the International Bureau).
   b. [X] has been transmitted by the International Bureau.
   c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US)
6. [X] A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. [X] are transmitted herewith (required only if not transmitted by the International Bureau).
   b. [X] have been transmitted by the International Bureau.
   c. [ ] have not been made; however, the time limit for making such amendments has NOT expired.
   d. [ ] have not been made and will not be made.
8. [X] A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. [X] An unexecuted oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. [X] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. [ ] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. [ ] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. [X] A FIRST preliminary amendment.
    [ ] A SECOND or SUBSEQUENT preliminary amendment.
14. [ ] A substitute specification.
15. [ ] A change of power of attorney and/or address letter.
16. [X] Other items or information:

    Thirty One (31) Sheets of formal drawings (Figs. 1-22); Copies of Written Opinion; International Search Report; International Preliminary Examination Report

EXPRESS MAIL "MAILING CERTIFICATE NO.": EL485953828US DATE OF DEPOSIT: MAY 26, 2000

526 Rec'd PCT/PTO 26 MAY 2000

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/555296	INTERNATIONAL APPLICATION NO PCT/GB98/03530	ATTORNEY'S DOCKET NUMBER 2369-1-002

17. ☒ The following fees are submitted:	CALCULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5)):		
Search Report has been prepared by the EPO or JPO $840.00		
International preliminary examination fee paid to USPTO (37 CFR 1.482) $670.00		
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) $760.00		
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO $970.00		
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) . . . . . $ 96.00		
ENTER APPROPRIATE BASIC FEE AMOUNT =	$ 840.00	
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	$	

Claims	Number Filed	Number Extra	Rate		
Total Claims	139 -20 =	119	X $ 18.00	$ 2,142.00	
Independent Claims	4 -3 =	1	X $ 78.00	$ 78.00	
Multiple dependent claim(s) (if applicable)			+ $260.00	$ 260.00	
TOTAL OF ABOVE CALCULATIONS =				$ 3,320.00	
Reduction for 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				$	-
SUBTOTAL =				$ 3,320.00	
Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +				$	
TOTAL NATIONAL FEE =				$ 3,320.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). $40.00 per property +				$	
TOTAL FEES ENCLOSED =				$ 3,320.00	
				Amount to be: refunded	$
				charged	$

a. ☒ A check in the amount of $ 3,320.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. 11-1153 in the amount of $_____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 11-1153. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

DAVID A. JACKSON
KLAUBER & JACKSON
411 HACKENSACK AVENUE
4TH FLOOR
HACKENSACK, NEW JERSEY 07601

SIGNATURE

NAME
David A. Jackson
REGISTRATION NUMBER 26,742

EXPRESS MAIL "MAILING CERTIFICATE NO.": EL485953828US DATE OF DEPOSIT: MAY 26, 2000

Patent
Attorney's Docket No. 2369-1-002

Applicant or Patentee: Patricia Anne NUTTALL and Guido Christian PAESEN

Application or Patent No.: 09/555,296

Filed or Issued: May 26, 2000

For: HISTAMINE AND SEROTONIN BINDING MOLECULES

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 C.F.R. §§ 1.9(f) AND 1.27(c)) - SMALL BUSINESS CONCERN

I hereby declare that I am

[ ] the owner of the small business concern identified below:
[X] an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN OXFORD VACS LTD.

ADDRESS OF CONCERN ~~160 Aldersgate Street, London, EC1A 4DD United Kingdom~~

Magdalen Centre, Oxford Science Park, Oxford, OX4 4GA United Kingdom

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 C.F.R. § 121.12, and reproduced in 37 C.F.R. § 1.9(d), for purposes of paying reduced fees under Sections 41(a) and 41(b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average, over the previous fiscal year of the concern, of the persons employed on a full-time, part-time, or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled Histamine and Serotonin Binding Molecules by inventor(s) NUTTALL; PAESEN described in

[ ] the specification filed herewith
[X] Application No. 09/555,296, filed May 26, 2000
[ ] Patent No. _____, issued _____.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern, or organization having rights to the invention is listed below,* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. § 1.9(c), or by any concern that would not qualify as either a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention averring to their status as small entities. (37 C.F.R. § 1.27.)

Attorney's Docket No. 2369-1-002

NAME OXFORD VACS LTD

ADDRESS ~~160 Aldersgate Street, London, EC1A 4DD United Kingdom~~

[ ] individual [X] small business concern [ ] nonprofit organization

Magdalen Centre, Oxford Science Park, Oxford, OX4 4GA United Kingdom

NAME _____

ADDRESS _____

[ ] individual [ ] small business concern [ ] nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earlier of the issue fee and any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b).)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code; and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING W. H. WESTON - DAVIES

TITLE OF PERSON OTHER THAN OWNER DIRECTOR, OXFORD VACS LTD

ADDRESS OF PERSON SIGNING EVOLVED LTD

THE MAGDALEN CENTRE, OXFORD SCIENCE PARK, OXFORD, OX4 4GA, UK

SIGNATURE _____ DATE 6/6/00

(4/94)

PATENT
2369-1-002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Patricia Ann Nuttall; Guido Christian Paesen

APPLICATION NO. : PCT/GB98/03530

FILED : 26 November 1998

FOR : HISTAMINE AND SEROTONIN BINDING MOLECULES

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
BOX PCT
WASHINGTON, D.C. 20231

Sir:

Prior to calculating the fees pursuant to the entry into the National Phase of the above-identified Application, please amend the claims as follows:

IN THE CLAIMS:

In Claim 6, line 1, delete "preceding claim" and insert --of Claims 1, 2 or 3--.

In Claim 7, line 1, delete "one of the preceding";

line 1, after "claims" insert --1, 2 or 3--.

In Claim 10, line 1, delete "to 9" and insert --, 2 or 3--.

Please delete Claims 11 to 17.

Please amend Claims 18, 19, 20 and 21 as follows:

18. (Amended) The histamine or serotonin binding compound or protein of any one of claims 1, 2, 3 or 51 [to 10 or protein according to any one of claims 11 to 17] produced by recombinant DNA technology.

19. (Amended) A histamine or serotonin binding compound or protein according to any one of [the preceding] claims 1, 2, 3 or 51 that binds specifically to histamine.

20. (Amended) The histamine or serotonin binding compound or protein of any one of [the preceding] claims 1, 2, 3 or 51 having an effector or reporter molecule attached hereto.

21. (Amended) The histamine or serotonin binding compound or protein of any [preceding claim] one of claims 1, 2, 3 or 51 that is derived from blood-feeding ectoparasites, spiders, scorpions or snakes and venomous animals.

In Claim 25, line 1, delete "the preceding";

line 2, after "claims" insert --1, 2, 3 or 51--.

In Claim 26, line 1, delete "the preceding";

line 2, after "claims" insert --1, 2, 3 or 51--.

In Claim 28, line 1, delete "the preceding";

line 2, after "claims" insert --1, 2, 3 or 51--.

In Claim 29, line 1, delete "the preceding";

line 2, after "claims" insert --1, 2, 3 or 51--.

In Claim 30, line 2, delete "the preceding";

line 2, after "claims" insert --1, 2, 3 or 51.

Please amend Claims 33 and 34 as follows:

33. (Amended) A vaccine comprising a histamine or serotonin binding compound or protein according to any one of claims 1[-10 or protein according to any one of claims 11-17] , 2, 3 or 51.

34. (Amended) The histamine or serotonin binding compound or protein according to any one of claims 1 [to 29 or composition of any one of claims 30 to 32] , 2, 3 or 51 for use in therapy.

Please delete Claims 35 to 38.

In Claim 39, lines 1 and 2, delete "to 29" and insert --, 2, 3 or 51;

line 3, after "material" insert --.--.

In Claim 40, line 1, delete "to 29" and insert --, 2, 3 or 51--.

In Claim 41, line 1, delete "to 29" and insert --, 2, 3, or 51--.

In Claim 42, lines 1 and 2, delete "to 29" and insert --, 2, 3 or 51--.

In Claim 43, lines 1 and 2, delete "to 29" and insert --2, 3 or 51--.

Please amend Claim 44 as follows:

44. (Amended) A method for treating or preventing inflammation or allergic reaction in humans or animals, comprising administering a therapeutically effective amount [The use] of a histamine or serotonin binding compound according to any one of claims 1 [to 29] , 2, 3 or 51 in conjunction with a pharmaceutically-acceptable carrier [in the manufacture of a medicament for the treatment or prevention of inflammation or allergic reaction in humans or animals].

In Claim 45, line 2, delete "to 29" and insert --, 2, 3 or 51--.

In Claim 47, line 2, delete "either of claims 45 or 46" and insert --Claim 45--.

In Claim 49, line 1, delete "either of claims 47 or 48" and insert --Claim 47--.

Please amend Claim 50 as follows:

50. (Amended) A transgenic animal that has been transformed by a nucleic acid molecule according to [either of] claim[s] 45 [or 46 or vector according to either of claims 47 or 48].

Please add the following new Claim 51:

--51. A protein selected from the group consisting of the Ra-Res amino acid sequence given in Figure 5, the Av-HBP amino acid sequence given in Figure 6, the Ih/Bm-HBP amino acid sequence given in Figure 7, the Ih/Bm-HBP2 amino acid sequence given in Figure 8, the Ih/Bm-HBP3 amino acid sequence given in Figure 9, the Ih/Bm-HBP4 amino acid sequence given in Figure 10, the Ih/Bm-HBP5 amino acid sequence given in Figure 11, functional equivalent derivatives or fragments thereof.--.

REMARKS

The above amendments are submitted herewith to reduce multiple dependencies and to conform the claims more closely to U.S. practice.

The amendments made herein are with respect to Claims 1-50, which claims were amended during the pendency of the International Application. A copy of Claims 1-50, which are included in the International Preliminary Examination Report, are enclosed herewith and attached hereto.

Entry of the foregoing amendments and early and favorable processing in the National Phase before the United States Patent and Trademark Office are courteously solicited.

Respectfully submitted,

DAVID A. JACKSON
Attorney for Applicant(s)
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, NJ 07601
(201) 487-5800

CLAIMS

1. A histamine or serotonin binding compound capable of binding to histamine or serotonin with a dissociation constant of less than 10^{-7}M and which has a binding site comprising amino acid residues phenylalanine, isoleucine or leucine at position I, tryptophan at position II and aspartate or glutamate at positions III and IV wherein residues I to IV are positioned substantially the same as residues 108, 42, 39 and 82 respectively in either of Figures 1 or 2, or residues 107, 41, 38 and 78 in Figure 3 or residues 122, 54, 50 and 95 in Figure 4, and functional equivalents thereof, wherein the numbering of the amino acid residues refers to the sequence of the mature protein that lacks the leader sequence.

2. A histamine or serotonin binding compound capable of binding to histamine or serotonin with a dissociation constant of less than 10^{-7}M and which has a binding site comprising amino acid residues phenylalanine or isoleucine at residue I, tryptophan at residue II and aspartate or glutamate at residues III and IV wherein residues I to IV are positioned substantially the same as residues 98, 137, 24 and 120 respectively in either of Figures 1 or 2, or residues 95, 138, 23 and 120 in Figure 3 or residues 112, 149, 35 and 135 in Figure 4, and functional equivalents thereof, wherein the numbering of the amino acid residues refers to the sequence of the mature protein that lacks the leader sequence.

3. A histamine binding compound capable of binding to histamine or serotonin with a dissociation constant of less than 10^{-7}M and which has two binding sites, the first binding site comprising amino acid residues phenylalanine, isoleucine or leucine at position I, tryptophan at position II and aspartate or glutamate at positions III and IV wherein residues I to IV are positioned substantially the same as residues 108, 42, 39 and 82 respectively in either of Figures 1 or 2, or residues 107, 41, 38 and 78 in Figure 3 or residues 122, 54, 50 and 95 in Figure 4, and the second binding site comprising amino acid residues phenylalanine or isoleucine at residue I, tryptophan at residue II and aspartate or glutamate at residues III and IV wherein residues I to IV are positioned substantially the same as residues 98, 137, 24 and 120 respectively in either of Figures 1 or 2, or residues 95, 138, 23 and 120 in Figure 3 or residues 112, 149, 35 and 135 in Figure 4, and functional equivalents thereof, wherein the

numbering of the amino acid residues refers to the sequence of the mature protein that lacks the leader sequence.

4. A histamine binding or serotonin binding compound according to claim 1 or 3 additionally comprising at residue V, a tyrosine residue, wherein residue V is positioned substantially the same as residue 100 in the sequence of either of Figures 1 or 2, residue 97 in Figure 3 or residue 114 in Figure 4, and functional equivalents thereof, wherein the numbering of the amino acid residues refers to the sequence of the mature protein that lacks the leader sequence.

5. A histamine or serotonin binding compound according to claim 2 or 3 additionally comprising at residue V, a tyrosine residue, wherein residue V is positioned substantially the same as residue 29 in the protein sequence of either of Figures 1 or 2, residue 28 in Figure 3 or residue 40 in Figure 4, and functional equivalents thereof, wherein the numbering of the amino acid residues refers to the sequence of the mature protein that lacks the leader sequence.

6. A histamine or serotonin binding compound according to any preceding claim wherein said compound is stabilised by either or both of the disulphide bridges formed between cysteines 48 and 169 and cysteines 148 and 119 in the protein sequence of either of Figures 1 or 2, cysteines 47 and 175 and cysteines 151 and 119 of Figure 3 or cysteines 162 and 134 of Figure 4, wherein the numbering of the amino acid residues refers to the sequence of the mature protein that lacks the leader sequence.

7. A histamine or serotonin binding compound of any one of the preceding claims which comprises a peptide, or a fragment of any one of the proteins whose amino acid sequences are presented in Figures 1-4.

8. The histamine or serotonin binding compound of claim 7 that comprises a cyclic peptide.

9. The histamine or serotonin binding compound of claim 8 wherein said cyclic peptide comprises the sequence Ala-Glu-Ala-Phe-Ala-Glu-Ala-Trp.

10. The histamine or serotonin binding compound of any one of claims 1 to 9 that comprises a synthetic compound.

11. A protein comprising the Ra-Res amino acid sequence given in Figure 5 or functionally equivalent derivative or functionally equivalent fragment thereof.

12. A protein comprising the Av-HBP amino acid sequence given in Figure 6 or functionally equivalent derivative or functionally equivalent fragment thereof.

13. A protein comprising the Ih/Bm-HBP1 amino acid sequence given in Figure 7 or functional equivalent derivative or fragment thereof.

14. A protein comprising the Ih/Bm-HBP2 amino acid sequence given in Figure 8 or functional equivalent derivative or fragment thereof.

15. A protein comprising the Ih/Bm-HBP3 amino acid sequence given in Figure 9 or functional equivalent derivative or fragment thereof.

16. A protein comprising the Ih/Bm-HBP4 amino acid sequence given in Figure 10 or functional equivalent derivative or fragment thereof.

17. A protein comprising the Ih/Bm-HBP5 amino acid sequence given in Figure 11 or functional equivalent derivative or fragment thereof.

18. The histamine or serotonin binding compound of any one of claims 1 to 10 or protein according to any one of claims 11 to 17 produced by recombinant DNA technology.

19. A histamine or serotonin binding compound or protein according to any one of the preceding claims that binds specifically to histamine.

20. The histamine or serotonin binding compound or protein of any one of the preceding claims having an effector or reporter molecule attached thereto.

21. The histamine or serotonin binding compound or protein of any preceding claim that is derived from blood-feeding ectoparasites, spiders, scorpions or snakes and venomous animals.

22. The histamine or serotonin binding compound or protein of claim 21 that is derived from ticks.

23. The histamine or serotonin binding compound or protein of claim 22 that is derived from Ixodid ticks.

24. The histamine or serotonin binding compound or protein of claim 23 that is derived from *Rhipicephalus appendiculatus, D. reticulatus, Amblyomma variegatum, Boophilus microplus or Ixodes hexagonus*.

25. The histamine or serotonin binding compound or protein of any one of the preceding claims associated with one or more carbohydrate moieties.

26. The histamine or serotonin binding compound or protein of any one of the preceding claims that is associated with one or more peptides or polypeptides.

27. The histamine or serotonin binding compound or protein of claim 26 that is genetically or chemically fused to one or more peptides or polypeptides.

28. The histamine or serotonin binding compound or protein of any one of the preceding claims attached to a label or toxin.

29. The histamine or serotonin binding compound or protein of any one of the preceding claims that is bound to a support, such as a resin.

30. A therapeutic or diagnostic composition comprising a histamine or serotonin binding compound or protein according to any one of the preceding claims.

31. A therapeutic or diagnostic composition according to claim 30 additionally comprising serotonin.

32. A therapeutic or diagnostic composition according to claim 31 additionally comprising a cysteinyl leukotriene, platelet activating factor, or a thromboxane.

33. A vaccine comprising a histamine or serotonin binding compound according to any one of claims 1-10 or protein according to any one of claims 11-17.

34. The histamine or serotonin binding compound or protein according to any one of claims 1 to 29 or composition of any one of claims 30 to 32 for use in therapy.

35. The histamine or serotonin binding compound or protein according to any one of claims 1 to 29 for use as a pharmaceutical.

36. Use of the histamine or serotonin binding compound or protein according to any one of claims 1 to 29 as a pharmaceutical.

37. The histamine or serotonin binding compound or protein according to any one of claims 1 to 29 for use in a vaccine.

38. Use of the histamine or serotonin binding compound or protein according to any one of claims 1 to 29 in a vaccine.

39. The histamine or serotonin binding compound or protein of any one of claims 1 to 29 for use in the detection or quantification of histamine in human, animal, plant, and food material

40. The histamine or serotonin binding compound of any one of claims 1 to 29 for use in the depletion or removal of histamine from food products, cell cultures or human, animal, plant and food material.

41. The histamine or serotonin binding compound of any one of claims 1 to 29 for use in the binding or detection of histamine in humans or animals.

42. The histamine or serotonin binding compound or protein of any one of claims 1 to 29 for use as an anti-histamine agent, an anti-inflammatory drug or in the treatment of allergy.

43. The histamine or serotonin binding compound or protein of any one of claims 1 to 29 for use as a tool in scientific research concerning the role of histamine in biological processes.

44. The use of a histamine or serotonin binding compound according to any one of claims 1 to 29 in conjunction with a pharmaceutically-acceptable carrier in the manufacture of a medicament for the treatment or prevention of inflammation or allergic reaction in humans or animals.

45. A nucleic acid compound which encodes a histamine or serotonin binding molecule or protein according to any one of claims 1 to 29 or which hybridises with said nucleic acid molecule under standard hybridisation conditions.

46. The nucleic acid molecule of claim 45 which comprises DNA, cDNA or RNA.

47. A cloning or expression vector comprising a nucleic acid molecule according to either of claims 45 or 46.

48. The vector of claim 47 which is virus based.

49. A host cell transformed or transfected with the vector of either of claims 47 or 48.

50. A transgenic animal that has been transformed by a nucleic acid molecule according to either of claims 45 or 46 or vector according to either of claims 47 or 48.

Histamine and Serotonin binding molecules

The present invention relates to histamine and serotonin binding molecules. More particularly, the present invention relates to molecules possessing a binding site with the precise molecular configuration that is necessary to confer on the molecule a high affinity for histamine. Included as embodiments of the present invention are those proteins, peptides and chemical compounds that possess this molecular configuration and that are thus able to bind to histamine with high affinity. The molecules of the present invention may be used in the regulation of the action of histamine or serotonin and are thus useful in the detection and quantification of histamine or serotonin and in the treatment of various diseases and allergies.

Vasoactive amines such as histamine and serotonin are mediators of inflammation and regulators of certain physiological processes in animals, including humans. Histamine is present in the secretory granules of mast cells and basophils and is formed by decarboxylation of histidine. It is also present in ergot and plants and may be synthesised synthetically from histidine or citric acid.

The main actions of histamine in humans are stimulation of gastric secretion, contraction of most smooth muscle tissue, cardiac stimulation, vasodilation and increased vascular permeability. In addition to its regulatory role in immune reactions and inflammatory processes, histamine also modulates the production of many cytokines in the body (including those that regulate inflammation) and can interfere with the expression of cytokine receptors. Furthermore, histamine promotes wound healing.

The main pathophysiological roles of histamine are as a stimulant of gastric acid secretion and as a mediator of type I hypersensitivity reactions such as urticaria and hay fever. Histamine and its receptors also have pathological aspects to their functions. They play dominant roles in allergies such as asthma, allergic rhinitis, atopic dermatitis and food and drug allergies, which affect a great number of people and are an important cause of illness and mortality. Histamine or its receptors may also be involved either directly or indirectly in autoimmune disease, e.g. arthritis, and in tumour growth (Falus, 1994).

The hormone serotonin (also known as 5-hydroxytryptamine) is both a vasoconstrictor and a neurotransmitter. It can also increase vascular permeability, induce dilation of capillaries and cause the contraction of nonvascular smooth muscle. Serotonin is present in the brain

and intestinal tissues and is produced by the pineal gland and by blood platelets. Pathological aspects related to serotonin include abnormal blood pressure, migraine, psychological disorders, respiratory disease and coronary heart disease. Serotonin agonists and antagonists are used to treat some of these disorders, but again often have undesirable side-effects.

Anti–histamine drugs are widely used, especially for the treatment of allergies. Most of these drugs are compounds that are structurally related to histamine, and bind to its receptor(s), thereby obstructing the interaction of histamine with its receptor(s). Such drugs as are currently available often have undesirable side effects (for example drowsiness) and are not always effective.

Histamine produces its actions by an effect on specific histamine receptors which are of three main types, H_1, H_2 and H_3, distinguished by means of selective antagonist and agonist drugs. Histamine H_1 and H_2 antagonists have clinical uses but at present histamine H_3 antagonists are used mainly as research tools. Intracellular histamine appears to be involved in cellular growth (tumour growth promotion) and tissue repair. Currently undefined intracellular histamine receptors are thought to be involved in these processes (Falus, 1994).

Histamine receptors have been the subject of concentrated research for a number of years. However, scant information is available regarding the structure of the active site of these molecules - in fact the H_3 receptor has not yet been cloned. The lack of any direct structural information for these proteins is presumably due to the fact that histamine receptor proteins are membrane proteins that denature in the absence of lipid and are consequently very difficult to crystallise.

Based on the fact that the H_1 and H_2-type receptors belong to the broad class of seven transmembrane G protein-coupled receptors, it can be assumed that they are mainly alpha-helical. A number of site-directed mutagenesis studies have been performed on these receptors that have indicated certain residues that are important for histamine binding. In the H_2 receptor, Asp^{98}, Asp^{186} and Thr^{190} are believed to contribute to the histamine binding pocket (Gantz *et al.*, 1992).

Conventional H_1 receptor antagonists are widely used as antihistamines for treating allergic reactions including allergic rhinitis (hay fever), urticaria, insect bites and drug hypersensitivities. Drugs that lack sedative or muscarinic receptor antagonists are

preferred. H_1 receptor antagonists are also used as anti-emetics for the prevention of motion sickness or other causes of nausea including severe morning sickness. Muscarinic receptor antagonist actions of some antihistamines probably contribute to efficacy but also cause side-effects. Some H_1 receptor antagonists are fairly strong sedatives and may be used for this action.

However, there are numerous undesirable effects of the H_1 receptor antagonists currently used. When used for purely antihistamine actions, all of the CNS effects are unwanted. When used for their sedative or anti-emetic actions, some of the CNS effects such as dizziness, tinnitus and fatigue are unwanted. Excessive doses can cause excitation and may produce convulsions in children. The peripheral anti-muscarinic actions are always undesirable. The commonest of these is dryness of the mouth, but blurred vision, constipation and retention of urine can also occur. Unwanted effects not related to the drug's pharmaceutical action are also seen. Thus, gastrointestinal disturbances are fairly common while allergic dermatitis can follow topical application of these drugs.

H_2 antagonists are frequently used as inhibitors of gastric acid secretion. They are used as the drugs of choice in the treatment of peptic ulcer, as second line drugs in the treatment of Zollinger-Ellison syndrome and for treating reflux oesophagitis. Unwanted effects have been reported that include diarrhoea, dizziness, muscle pains, transient rashes and hyper-gastrinaemia. Some H_2 receptor antagonists can cause gynaecomastia in men and confusion in the elderly.

Besides these unwanted effects, some histamine antagonists are troublesome if taken with alcohol or with drugs. For example, the antihistamine Seldane used in combination with antibiotics and antifungals may cause life-threatening side-effects.

It can therefore be seen that drugs used to control the actions of histamine are not always effective. The reasons why they may have limited efficacy may relate to the specificity of these drugs for only a sub-class of histamine receptors, particularly when a certain class of conditions require interference with a larger class of receptors. Molecules that actually bind to histamine itself would compete for histamine binding with all receptors and may thus be more suitable for treating certain conditions.

There is thus a great need for effective antagonists of histamine and serotonin that do not generate the side-effects that detract from their applicability to the treatment of human and animal disorders.

There is also a great need for the quantification of histamine in, for example, food products, various bodily fluids (e.g. plasma or urine) or cell culture supernatants to monitor the effects of certain allergens, for example, or to indicate a potential specific antagonistic therapy for an allergic reaction. Currently-used systems (radioimmunoassays and ELISAs) utilise antibodies against histamine or against histamine derivatives. However, histamine is not very immunogenic, making it hard to raise high affinity antibodies against it, and most of the quantification systems that are currently used are not very sensitive or require modification of the histamine to be measured (for example by methylation or acylation). The use of molecules that bind to histamine in its natural form that would replace antibodies in assays like these would provide a highly sensitive system for the measurement of unmodified histamine. Similarly, molecules that bind to serotonin could be used for the quantification of this molecule.

Molecules capable of binding to histamine have previously been identified in blood-feeding ectoparasites. For example, a salivary nitric oxide–carrying haeme protein (nitrophorin) of the triatome bug *Rhodnius prolixus* has been found to bind histamine (Ribeiro and Walker, 1994). The isolation of four vasoactive amine binding proteins (VABPs) from ticks is described in co-pending International Patent Application No. PCT/GB97/01372 which is owned by the Applicant for the present invention. The contents of PCT/GB97/01372 are incorporated into the present application in their entirety.

These proteins bind to histamine and are closely related to one another. They are named MS-HBP1, FS-HBP1, FS-HBP2 and D.RET6. Some of these molecules also bind serotonin (for example FS-HBP2). In other cases, such as in the case of D.RET6 for example, binding of serotonin is thought to alter the affinity of the molecule for histamine. The DNA sequences that encode these proteins are presently being used to isolate other related proteins in the same family from the same and different species.

These molecules appear to differ markedly from histamine binding proteins from any of the H_1, H_2 or H_3 families and appear to bind to histamine in a different manner. The elucidation of the structure of the histamine binding site of these molecules would markedly accelerate the rational design of effective histamine antagonists that would be unlikely to suffer from the side-effects which are associated with conventional anti-histamine agents.

Summary of the invention

According to a first aspect of the present invention there is provided a histamine or serotonin binding compound capable of binding to histamine or serotonin with a dissociation constant of less than 10^{-7}M and which has a binding site comprising amino acid residues phenylalanine, isoleucine or leucine at position I, tryptophan at position II and aspartate or glutamate at positions III and IV wherein residues I to IV are positioned substantially the same as residues 108, 42, 39 and 82 respectively in either of SEQ. ID. Nos 1 or 2, or residues 107, 41, 38 and 78 in SEQ ID 3 or residues 122, 54, 50 and 95 in SEQ ID 4, and functional equivalents thereof. Hereafter, this binding site will be referred to as the "first binding site". The proteins identified in SEQ IDs 1 to 4 are known as FS-HBP1, FS-HBP2, MS-HBP and D.RET6 respectively.

According to a second aspect of the present invention there is provided a histamine or serotonin binding compound capable of binding to histamine or serotonin with a dissociation constant of less than 10^{-7}M and which has a binding site comprising amino acid residues phenylalanine or isoleucine at residue I, tryptophan at residue II and aspartate or glutamate at residues III and IV wherein residues I to IV are positioned substantially the same as residues 98, 137, 24 and 120 respectively in either of SEQ. ID. Nos 1 or 2, or residues 95, 138, 23 and 120 in SEQ. ID. 3 or residues 112, 149, 35 and 135 in SEQ. ID. 4, and functional equivalents thereof. Hereafter, this binding site will be referred to as the "second binding site".

According to a third aspect of the invention there is provided a histamine or serotonin binding compound capable of binding to histamine or serotonin with a dissociation constant of less than 10^{-7}M and which comprises both the first and second binding sites described above, and functional equivalents thereof. For some histamine binding compounds containing both the first and second binding sites (such as D.RET6), binding of serotonin to the compound is thought to alter the affinity of the compound for histamine.

Other chemical compounds with a related action to serotonin may also influence the binding of histamine to a histamine binding compound containing both the first and the second binding sites. These related compounds include cysteinyl leukotrienes (such as leukotriene D_4 and leutkotriene E_4), platelet activating factor and thromboxanes.

According to a fourth aspect of the present invention there is provided a histamine or serotonin binding compound capable of binding to histamine or serotonin with a dissociation constant of less than 10^{-7}M and which comprises the sequence of D.RET6 (SEQ. ID. 4) or a fragment thereof and which comprises a first and second binding site as defined above, or functional equivalents thereof, wherein binding of serotonin to the compound increases the affinity of the compound for histamine.

By binding site is meant the specific region in the compound that contributes directly to the binding of a histamine or serotonin molecule. As such, binding at this site will comprise molecular recognition events between the binding site and the histamine or serotonin molecule, regulated by functional complementarities of shape, size, charges, H-bonds, hydrophobic and pi interactions and van der Waal's forces. Interactions may also comprise covalent chemical bonds.

By the term " functional equivalent" is meant compounds that possess the desired binding site and includes any macromolecule or molecular entity that binds to histamine or serotonin with a dissociation constant of 10^{-7}M or less and that possesses an equivalent complementarity of shape to that possessed by the binding sites of the histamine or serotonin binding molecules identified in any of SEQ IDs 1 to 4. A functionally equivalent complementarity of shape may be provided by any hydrogen, oxygen, phosphorus and nitrogen atoms that are positioned substantially as identified in the structures disclosed herein.

Current methods of generation of compounds with affinity for a molecule of interest have been until recently relatively primitive. The notion of combinatorial chemistry and the generation of combinatorial libraries has, however, developed at great speed and facilitated the rational design and improvement of molecules with desired properties. These techniques can be used to generate molecules possessing binding sites identical or similar to those of the histamine or serotonin binding sites identified herein.

Such compounds may be generated by rational design, using for example standard synthesis techniques in combination with molecular modelling and computer visualisation programs. Under these techniques, the "lead" compound with a similar framework to the histamine or serotonin binding site is optimised by combining a diversity of scaffolds and component substituents.

Alternatively, or as one step in the structure-guided design of a molecular entity, combinatorial chemistry may be used to generate or refine the structure of compounds that mimic the histamine or serotonin binding site of histamine or serotonin binding compounds by the production of congeneric combinatorial arrays around a framework scaffold. These steps might include standard peptide or organic molecule synthesis with a solid-phase split and recombine process or parallel combinatorial unit synthesis using either solid phase or solution techniques (see, for example Hogan, 1997 and the references cited therein).

Alternatively, or as a portion of a histamine or serotonin binding molecule of the present invention, functional equivalents may comprise fragments or variants of the proteins identified in Figures 1 to 4 or closely related proteins exhibiting significant sequence homology. By fragments is meant any portion of the entire protein sequence that retains the ability to bind to vasoactive amines with a dissociation constant of 10^{-7}M or less. Accordingly, fragments containing single or multiple amino acid deletions from either terminus of the protein or from internal stretches of the primary amino acid sequence form one aspect of the present invention. Variants may include, for example, mutants containing amino acid substitutions, insertions or deletions from the wild type sequence of Figures 1 to 4.

The man of skill in the art will understand that the residues that contribute to the binding of vasoactive amines in the four proteins explicitly identified herein are maintained in the relevant position for binding to histamine or serotonin through the framework structure of the protein. Thus, the framework residues of the proteins are responsible for the exact positioning of the binding amino acids.

Accordingly, it is contemplated that any molecular framework capable of retaining these amino acid side-chains in the necessary positions for binding to histamine or serotonin will be suitable for use in accordance with the present invention. Of particular suitability will be cyclic peptides held in a precise framework by their linking groups and bonds. The amino acid side chains may be held in a position substantially identical to their position in the histamine or serotonin binding site of native histamine or serotonin binding compounds. Preferably, the cyclic peptides comprise between 6 and 30 amino acids, preferably between 8 and 20 amino acids. Of particular suitability is the cyclic octapeptide Ala-Glu-Ala-Phe-Ala-Glu-Ala-Trp.

Biologically-active peptides with histamine or serotonin binding sites according to the present invention may be generated using phage libraries. Nucleic acids encoding amino acid residues identified as participants in the binding of histamine or serotonin, together with nucleic acid encoding the surrounding framework residues may be fused to give a polypeptide unit of between 10 and 1000 residues, preferably between 25 and 100 residues. By fusion of this nucleic acid fragment with that encoding a phage protein, for example pIII of the bacteriophage fd, the fusion molecule may be displayed on the surface of phage. Screening of the phage library with histamine or serotonin will then identify those clones of interest. These clones can then be subjected to iterative rounds of mutagenesis and screening to improve the affinity of the generated molecules for histamine or serotonin.

Residues with analogous physical properties to those that comprise the histamine or serotonin binding site may also form part of a molecule according to the present invention. For example, with respect to the protein FS-HBP2, either of the charged residues glutamate or aspartate may occupy position 39 and 82 in the sequence. At position 108 in the sequence, it is envisaged that any hydrophobic amino acid residue may occupy this site, provided that steric concerns are satisfied with respect to the molecular configuration of the binding site. Phenylalanine, isoleucine and leucine are preferable residues at this position. At position 42, tryptophan is preferred.

Additionally, at position 100 in the histamine binding compound sequence, it is preferred that a tyrosine residue is present. This molecule is thought to contribute to the stability of histamine in the binding site. Any molecular structure that retains this amino acid side-chain or an equivalent in this position forms an aspect of the present invention.

Due to variations in the length and sequence of the four proteins explicitly described herein, the method of numbering residues differs between proteins. However, it will be apparent from the alignment shown in Figure 22 which residues correspond to the residues numbered according to the sequence of FS-HBP2.

It is envisaged that proteins according to the present invention may be stabilised by the presence of disulphide bridges in the structure. For example, the cysteines found in positions 48, 169, 119 and 148 of FS-HBP2 are conserved in all four histamine binding proteins identified so far. Two disulphide bridges are formed in FS-HBP2, one between cysteines 48 and 169, the other between 148 and 119. Accordingly, for any protein

fragment designed to mimic the structure of the natural histamine or serotonin binding compound binding site, these cysteine residues may be present in the sequence so that one or both disulphide bridges form within the protein structure.

It is preferred that in addition to the high affinity with which the compounds of the present invention bind to histamine or serotonin, this binding phenomenon is also specific for histamine or serotonin. The advantages that this specificity confer on the compounds will be obvious to the man of skill in the art. For example, for use as a pharmaceutical or in the quantification of the histamine content of a solution, it is of the utmost importance that compounds other than histamine are not bound by the compounds of the present invention. In the case of a pharmaceutical, lack of specificity might lead to unwanted side-effects; used in the quantification of histamine, non-specificity would lead to misleading and inaccurate results.

According to a fifth aspect of the invention there is provided a protein comprising the amino acid sequence given in SEQ. ID. No. 5. This sequence encodes a salivary *Rhipicephalus appendiculatus* protein termed Ra-Res. Its primary sequence was inferred from a cDNA that was obtained by screening a *R. appendiculatus* salivary gland cDNA library with the antiserum from a guinea pig which had developed resistance against *R. appendiculatus* ticks.

According to a sixth aspect of the invention there is provided a protein comprising the amino acid sequence given in SEQ. ID. No. 6. This sequence codes for a protein termed Av-HBP from *Amblyomma variegatum* ticks. Preliminary results of histamine-binding studies suggest an equilibrium dissociation constant (Kd) of 7.3 nM.

According to a seventh aspect of the invention there is provided a protein comprising the amino acid sequence given in either SEQ. ID. No. 7 or SEQ. ID. No.8. These sequences encode proteins termed Ih/Bm-HBP1 and Ih/Bm-HBP2 respectively and were isolated from a mixed *Boophilus microplus/Ixodes hexagonus* cDNA expression library. The library was screened with probes constructed from RT-PCR products obtained from *Boophilus microplus /Ixodes hexagonus* salivary gland RNA, using degenerate primers of which the design was based on conserved domains within the *R. appendiculatus* HBPs (FS-HBP1, FS-HBP2. MS-HBP1 and D.RET6).

According to an eighth aspect of the invention there is provided a protein comprising the amino acid sequence given in SEQ.ID. No. 9, the amino acid sequence given in

SEQ.ID. No. 10, the amino acid sequence given in SEQ.ID. No. 11. These sequences encode proteins termed Ih/Bm-HBP3, Ih/Bm-HBP4, and Ih/Bm-HBP5 respectively. These sequences were also isolated from the mixed *Boophilus microplus/Ixodes hexagonus* cDNA expression library mentioned above. Their sequences show convincing sequence similarity with the *R. appendiculatus* HBPs (FS-HBP1, FS-HBP2. MS-HBP1 and D.RET6), but also contain extensive domains that are not present in the traditional sequences (see Figure 22).

As will be clear to the man of skill in the art, the invention includes functionally-equivalent derivatives and fragments of the protein sequences given in SEQ.ID. Nos. 6 to 11. "Functionally-equivalent" is used in this context to indicate derivatives and fragments that retain the capacity to bind to vasoactive amines or that contain epitopes which can be used in the development of vaccines of antibodies that target any one of the proteins Ra-Res, Av-HBP, Ih/Bm-HBP1, Ih/Bm-HBP2, Ih/Bm-HBP3, Ih/Bm-HBP4, or Ih/Bm-HBP5. The derivatives may be derived from the wild type sequences of these proteins by single or multiple amino acid substitutions, additions, insertion and/or deletions or by chemical modification of one or more of the amino acids, for instance by deglycosylation of glycosylated forms.

The invention also includes proteins in the same family as Ra-Res, Av-HBP, Ih/Bm-HBP1, Ih/Bm-HBP2, Ih/Bm-HBP3, Ih/Bm-HBP4, or Ih/Bm-HBP5. A protein is considered to belong to the same family as any one of these proteins if 40% or more of the amino acids in the sequence are conserved. For examples, proteins may be compared in this manner using GCG's pileup command (Program manual for the Wisconsin package, 1994; gap creating penalty = 2.50; gap extension penalty = 0.05).

The proteins of these aspects of the invention include natural biological variants or geographical variations within the species from which the proteins are derived.

For instance, a derivative may include an additional protein or polypeptide fused to one of these proteins at its amino- or carboxy- terminus, or added internally in the sequence. The purpose of the additional polypeptide may be to aid detection, expression of separation or purification of the protein or may be to lend additional properties to the protein as desired.

Synthetic molecules designed to mimic the tertiary structure or active site of the Ra-Res, Av-HBP, Ih/Bm-HBP1, Ih/Bm-HBP2, Ih/Bm-HBP3, Ih/Bm-HBP4, or Ih/Bm-

HBP5 proteins constitute a further aspect of the invention.

For many applications, compounds according to the present invention may be fused to an effector or reporter molecule such as a label, toxin or bioactive molecule. Such molecules may comprise an additional protein or polypeptide fused to the histamine or serotonin binding compound at its amino- or carboxy-terminus or added internally. The purpose of the additional polypeptide may be to aid detection, expression, separation or purification of the histamine or serotonin binding compound or may be to lend additional properties to the compound as desired.

Particularly suitable candidates for fusion will be reporter molecules such as luciferase, green fluorescent protein, or horse radish peroxidase. Labels of choice may be radiolabels or molecules that are detectable spectroscopically, for example fluorescent or phosphorescent chemical groups. Linker molecules such as streptavidin or biotin may also be used. Additionally, other peptides or polypeptides may be fused to a histamine or serotonin binding compound. Suitable peptides may be, for example, β-galactosidase, glutathione-S-transferase, luciferase, polyhistidine tags, secretion signal peptides, the Fc region of an antibody, the FLAG peptide, cellulose binding domains, calmodulin and the maltose binding protein. Antibodies or peptides used to target the histamine or serotonin binding compounds more efficiently towards a site of action (for example antibodies against membrane proteins of mast cells) may also be fused to the histamine or serotonin binding compounds.

These fusion molecules may be fused chemically, using methods such as chemical cross-linking. Suitable methods will be well known to those of skill in the art and may comprise for example, cross-linking of the thiol groups of cysteine residues or cross-linking using formaldehydes. Chemical cross-linking will in most instances be used to fuse non-protein compounds, such as cyclic peptides and labels.

When it is desired to fuse two protein molecules, the method of choice will often be to fuse the molecules genetically. In order to generate a recombinant fusion protein, the genes or gene portions that encode the proteins or protein fragments of interest are engineered so as to form one contiguous gene arranged so that the codons of the two gene sequences are transcribed in frame.

The compounds of the present invention may also comprise histamine or serotonin binding compounds bound to a support that can be used to remove, isolate or extract histamine or

serotonin from body tissues, blood or food products. The support may comprise any suitably inert material and includes gels, magnetic and other beads, microspheres, binding columns and resins.

If proteinaceous, the histamine or serotonin binding compound may be derived from any organism possessing a protein in the same family as the histamine or serotonin binding compounds identified to date. By protein family is meant a group of polypeptides that share a common function and exhibit common sequence homology between motifs present in the polypeptide sequences. By sequence homology is meant that the polypeptide sequences are related by divergence from a common ancestor.

Preferably, proteins or protein fragments are derived from blood-feeding ectoparasites, spiders, scorpions or snakes or other venomous animals. More preferably, the proteins or protein fragments are derived from ticks, most preferably Ixodid ticks such as, for example, *Rhipicephalus appendiculatus*.

Most preferably, proteinaceous compounds according to the present invention are derived from any one of the proteins FS-HBP1, FS-HBP2, MS-HBP1, D.RET6, Ra-Res, Av-HBP, Ih/Bm-HBP1, Ih/Bm-HBP2, Ih/Bm-HBP3, Ih/Bm-HBP4, or Ih/Bm-HBP5.

Protein or peptide compounds according to the invention will preferably be expressed in recombinant form by expression of the encoding DNA in an expression vector in a host cell. Such expression methods are well known to those of skill in the art and many are described in detail in *DNA cloning: a practical approach, Volume II: Expression systems*, edited by D.M. Glover (IRL Press, 1995) or in *DNA cloning: a practical approach, Volume IV: Mammalian systems*, edited by D.M. Glover (IRL Press, 1995). Protein compounds may also be prepared using the known techniques of genetic engineering such as site-directed or random mutagenesis as described, for example, in *Molecular Cloning: a Laboratory Manual*: 2nd edition, (Sambrook *et al.*, 1989, Cold Spring Harbor Laboratory Press) or in *Protein Engineering: A practical approach* (edited by A.R. Rees *et al.*, IRL Press 1993).

Suitable expression vectors can be chosen for the host of choice. The vector may contain a recombinant DNA molecule encoding compounds of the present invention operatively linked to an expression control sequence, or a recombinant DNA cloning vehicle or vector containing such a recombinant DNA molecule under the control of a promoter recognised by the host transcription machinery.

Suitable hosts include commonly used prokaryotic species, such as *E. coli*, or eukaryotic yeasts that can be made to express high levels of recombinant proteins and that can easily be grown in large quantities. Mammalian cell lines grown *in vitro* are also suitable, particularly when using virus-driven expression systems such as the baculovirus expression system which involves the use of insect cells as hosts. Compounds may also be expressed *in vivo*, for example in insect larvae or in mammalian tissues.

According to a ninth aspect of the present invention there is provided a pharmaceutical composition comprising a histamine or serotonin binding compound according to the first or second aspect of the invention or a protein according to the third, fourth, fifth, sixth, seventh or eighth aspects of the invention, in conjunction with a pharmaceutically-acceptable excipient. Suitable excipients will be well known to those of skill in the art and may, for example, comprise a phosphate-buffered saline (0.01M phosphate salts, 0.138M NaCl, 0.0027M KCl, pH7.4). Pharmaceutical compositions may also contain additional preservatives to ensure a long shelf life in storage.

According to a yet further aspect, the present invention provides for the use of the histamine or serotonin binding compounds of the first, second, third or fourth aspects of the invention, of a protein according to the fifth, sixth, seventh or eighth aspects of the invention or of the pharmaceutical compositions of the ninth aspect of the invention in therapy. The histamine or serotonin binding compounds, proteins or compositions may be used as anti-inflammatory agents or may be used to bind histamine or serotonin in mammals, thereby to regulate their action and to control their pathological effects. This causes their sequestration and so lowers the effective concentration of histamine or serotonin in the body. This results in a tempered or even entirely abrogated physiological response, depending upon the dosage used. The histamine or serotonin binding compounds of the present invention may also be used as anti–inflammatory agents or agents to counter the effects of allergic reactions in the body.

According to this aspect of the invention, the histamine or serotonin binding compounds, proteins or compositions may be used in conjunction with serotonin in order to alter the affinity of the compounds for histamine. For example, for the compound D.RET6 it is shown herein that serotonin significantly increases the affinity of the compound for histamine. Compounds related in action to serotonin may also be

used, such as cysteinyl leukotrienes (such as leukotriene D_4 or leutkotriene E_4), platelet activating factor, or thromboxanes.

The histamine or serotonin binding compound according to the first, second, third or fourth aspects of the invention or protein according to the fifth, sixth, seventh or eighth aspects of the invention may constitute the sole active component of the composition or can form part of a therapeutic package, such as a component of creams for topical administration to insect, snake or scorpion bites, or to skin affected by dermatitis. The proteins may also be used as carrier molecules for histamine or serotonin and histamine or serotonin–related compounds, in creams, oils, powders or pills, to provide slow release of the bound histamine or serotonin.

The invention also comprises the use of the compounds of the present invention as histamine or serotonin binding components in kits for the detection or quantification of histamine or serotonin levels (for example, in blood, nasal lavage fluid, tissues or food products). Such a kit will resemble a radio-immunoassay kit and would comprise a histamine or serotonin binding compound according to the present invention and detection means that allows the accurate quantification of the amount of histamine or serotonin in the fluid. A set amount of radiolabelled histamine or serotonin, for example tritiated histamine or tritiated serotonin, is added to the sample to be measured. The histamine or serotonin in the sample will then compete with the labelled histamine or serotonin for binding to the limited amount of binding sites possessed by the histamine or serotonin binding compounds also present in the sample. The amount of histamine or serotonin present in the sample can thus be accurately assessed.

One aspect of the present invention comprises such kits incorporating the histamine or serotonin binding compounds of the present invention. The histamine or serotonin binding compounds may be bound to magnetic beads, agarose beads or may be fixed to the bottom of a multiwell plate. This will allow the removal of the unbound labelled histamine or serotonin from the sample after incubation. Alternatively the protein may be bound to SPA (Scintillation Proximity Assay) beads, in which case there is no need to remove unbound ligand. Using a set of unlabelled histamine or serotonin standards, the results obtained with these standards can be compared with the results obtained with the sample to be measured.

The histamine or serotonin binding compounds of the first, second, third or fourth aspects of the invention, or proteins according to the fifth, sixth, seventh or eighth aspects of the invention can also be used for the detection of histamine or serotonin. Any technique common to the art may be used in such a detection method and may comprise the use of blotting techniques (Towbin *et al*, 1979), binding columns, gel retardation, chromatography, or any of the other suitable methods that are widely used in the art. In another embodiment, the histamine or serotonin binding compound may be fused either genetically or synthetically to another protein such as alkaline phosphatase, luciferase or peroxidase in order to facilitate its detection.

It may be preferred to include serotonin or a related compound in the kits according to this aspect of the invention in order to alter the affinity of the histamine binding compound for histamine. Such related compounds include cysteinyl leukotrienes (such as leukotriene D_4 or leukotriene E_4), platelet activating factor, and thromboxanes. This will be particularly preferred when the compound D.RET6 or a functional equivalent thereof is used as the active histamine binding compound of the kit.

The invention also comprises the use of the histamine or serotonin binding compounds of the first, second, third or fourth aspects of the invention, or proteins according to the fifth, sixth, seventh or eighth aspects of the invention as histamine or serotonin –binding entities bound to a support that can be used to remove, isolate or extract histamine or serotonin (from body tissues, blood or food products). The support may comprise any suitable material and includes gels, beads, microspheres, binding columns and resins. The histamine or serotonin binding compound can, for example, be chemically or enzymatically linked to reactive groups on these supports.

The present invention also includes the use of a histamine or serotonin binding compound of the first, second, third or fourth aspects of the invention, or of a protein according to the fifth, sixth, seventh or eighth aspects of the invention as tools in the study of inflammation, inflammation–related processes or other physiological effects of vasoactive amines such as the role of histamine in the formation of gastric ulcers. For example, the histamine or serotonin binding compounds may be used for histamine or serotonin depletion in cell cultures or in inflamed animal tissues, in order to study the importance of histamine or serotonin in these systems. The histamine or serotonin

binding compounds may be pre-incubated with serotonin, or a related compound to increase the affinity of the compounds for histamine.

The present invention also provides for the use of the histamine or serotonin binding compounds of the first, second, third or fourth aspects of the invention, and of a protein according to the fifth, sixth, seventh or eighth aspects of the invention as immunogens for use as metazoan parasite vaccines and in particular as protective immunogens in the control of diseases caused by arthropod and other metazoan parasites. Suitable candidates for vaccination include domesticated animals such as cattle, goats, sheep, dogs, cats and other animals that require protection against metazoan parasites, especially ticks. The vaccine may include adjuvants of the type which are well known in the art.

Nucleic acid molecules comprising a nucleotide sequence encoding a histamine or serotonin binding compound of the first, second, third or fourth aspects of the invention, or encoding a protein according to the fifth, sixth, seventh or eighth aspects of the invention form further aspects of the invention. These molecules include DNA, cDNA and RNA, as well as synthetic nucleic acid species.

Complementary DNAs encoding particular histamine or serotonin binding molecules according to the proteins FS-HBP1, FS-HBP2, MS-HBP1, D.RET6, Ra-Res, Av-HBP, Ih/Bm-HBP1, Ih/Bm-HBP2, Ih/Bm-HBP3, Ih/Bm-HBP4, or Ih/Bm-HBP5 are disclosed herein in Figures 1 to 11 (nucleotides and amino acids are given in their standard one letter abbreviations).

The preferred nucleic acid molecule, according to the invention, comprises a nucleotide fragment identical to or complementary to any portion of any one of the nucleotide sequences shown in Figures 1 to 11 that encodes a histamine or serotonin binding compound, or a sequence which is degenerate or substantially homologous therewith, or which hybridises with the said sequence. By 'substantially homologous' is meant sequences displaying at least 60% sequence homology. 'Hybridising sequences' included within the scope of the invention are those binding under standard non–stringent conditions (6 X SSC/50% formamide at room temperature) and washed under conditions of low stringency (2 x SSC, room temperature, or 2 x SSC, 42°C) or preferably under standard conditions of higher stringency, e.g. 0.1 x SSC, 65°C (where SSC = 0.15M NaCl, 0.015M sodium citrate, pH 7.2).

The nucleic acid sequences according to the invention may be single- or double–stranded DNA, cDNA or RNA. Preferably, the nucleic acid sequences comprise DNA.

The invention also includes cloning and expression vectors containing the DNA sequences of the invention. Such expression vectors will incorporate the appropriate transcriptional and translational control sequences, for example enhancer elements, promoter–operator regions, termination stop sequences, mRNA stability sequences, start and stop codons or ribosomal binding sites, linked in frame with the nucleic acid molecules of the invention.

Additionally, in the absence of a naturally-effective signal peptide in the protein sequence, it may be convenient to cause the recombinant protein to be secreted from certain hosts. Accordingly, further components of such vectors may include nucleic acid sequences encoding secretion signalling and processing sequences.

Vectors according to the invention include plasmids and viruses (including both bacteriophage and eukaryotic viruses). Many such vectors and expression systems are well known and documented in the art. Particularly suitable viral vectors include baculovirus-, adenovirus- and vaccinia virus-based vectors.

The expression of heterologous polypeptides and polypeptide fragments in prokaryotic cells such as *E. coli* is well established in the art; see for example *Molecular Cloning: a Laboratory Manual*: 2nd edition, Sambrook *et al.*, 1989, Cold Spring Harbor Laboratory Press or *DNA cloning: a practical approach, Volume II: Expression systems*, edited by D.M. Glover (IRL Press, 1995). Expression in eukaryotic cells in culture is also an option available to those skilled in the art for the production of heterologous proteins; see for example O'Reilly *et al.*, (1994) *Baculovirus expression vectors - a laboratory manual* (Oxford University Press) or *DNA cloning: a practical approach, Volume IV: Mammalian systems*, edited by D.M. Glover (IRL Press, 1995) .

Suitable vectors can be chosen or constructed for expression of histamine or serotonin binding proteins, containing the appropriate regulatory sequences, including promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. Vectors may be plasmids, viral e.g. bacteriophage, or phagemid, as appropriate. For further details see *Molecular Cloning: a Laboratory Manual*. Many known techniques and protocols for manipulation of nucleic acid, for example, in the preparation of nucleic acid constructs, mutagenesis,

sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in *Short Protocols in Molecular Biology*, Second Edition, Ausubel *et al.* eds., (John Wiley & Sons, 1992) or *Protein Engineering: A practical approach* (edited by A.R. Rees *et al.*, IRL Press 1993). For example, in eukaryotic cells, the vectors of choice are virus-based.

A further aspect of the present invention provides a host cell containing a nucleic acid encoding a histamine or serotonin binding compound of the first, second, third or fourth aspects of the invention, or encoding a protein according to the fifth, sixth, seventh or eighth aspects of the invention. A still further aspect provides a method comprising introducing such nucleic acid into a host cell or organism.

Introduction of nucleic acid may employ any available technique. In eukaryotic cells, suitable techniques may include calcium phosphate transfection, DEAE-Dextran, electroporation, liposome-mediated transfection or transduction using retrovirus or other viruses, such as vaccinia or, for insect cells, baculovirus. In bacterial cells, suitable techniques may include calcium chloride transformation, electroporation or transfection using bacteriophage.

Introduction of the nucleic acid may be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells under conditions for expression of the gene.

In one embodiment, the nucleic acid of the invention is integrated into the genome (e.g. chromosome) of the host cell. Integration may be promoted by inclusion of sequences which promote recombination with the genome, in accordance with standard techniques.

Transgenic animals transformed so as to express or overexpress in the germ line one or more histamine or serotonin binding compounds as described herein form a still further aspect of the invention, along with methods for their production. Many techniques now exist to introduce transgenes into the embryo or germ line of an organism, such as for example, illustrated in Watson *et al.*, (1994) Recombinant DNA (2nd edition), Scientific American Books.

A variety of techniques are known and may be used to introduce the vectors according to the present invention into prokaryotic or eukaryotic cells. Suitable transformation or transfection techniques are well described in the literature *Molecular Cloning: a*

Laboratory Manual: 2nd edition, (Sambrook *et al.*, 1989, Cold Spring Harbor Laboratory Press). In eukaryotic cells, expression systems may either be transient (e.g. episomal) or permanent (chromosomal integration) according to the needs of the system. See, for example *Short Protocols in Molecular Biology*, Second Edition, Ausubel *et al.* eds., (John Wiley & Sons, 1992).

All documents mentioned in the text are incorporated herein by reference.

Various aspects and embodiments of the present invention will now be described in more detail by way of example, with particular reference to proteinaceous histamine or serotonin binding compounds isolated from ticks. It will be appreciated that modification of detail may be made without departing from the scope of the invention.

Brief description of Figures

Figure 1 is the sequence of FS-HBP1 (SEQ. ID. 1), showing sequencing primers and sequencing strategy.

Figure 2 is the sequence of FS-HBP2 (SEQ ID 2), showing sequencing primers and sequencing strategy.

Figure 3 is the sequence of MS-HBP1 (SEQ ID 3), showing sequencing primers and sequencing strategy.

Figure 4 is the sequence of D.RET6 (SEQ ID 4), showing sequencing primers and sequencing strategy.

Figure 5 is the sequence of ra-RES (SEQ. ID. 5). Asparagines that are part of putative glycosylation recognition sites are underlined and shown in italics. The squiggly line denotes a possible amidation site I; the double line indicates the putative polyadenylation signal and the polyA-tail is shown in bold letter type.

Figure 6 is the sequence of Av-HBP (SEQ. ID. 6). Sequence of the Av-HBP cDNA and its inferred primary structure. The cDNA has a remarkably long non-coding region, downstream of the stop codon.

Figure 7 is the sequence of Ih/Bm-HBP1 (SEQ. ID. 7).

Figure 8 is the sequence of Ih/Bm-HBP2 (SEQ. ID. 8).

Figure 9 is the sequence of Ih/Bm-HBP3 (SEQ. ID. 9).

Figure 10 is the sequence of Ih/Bm-HBP4 (SEQ. ID. 10).

Figure 11 is the sequence of Ih/Bm-HBP5 (SEQ. ID. 11).

Figure 12 is a silver-stained 12% SDS-polyacrylamide gel showing fractions obtained from a nickel resin column used to purify recombinant D.RET6 expressed in insect cells. A, flow-through fraction; B, first wash fraction (10 volumes of phosphate buffer pH 6.5); C, second wash fraction (with 5mM imidazole); D, third wash fraction (with 10mM imidazole); E, fourth wash fraction (with 15 mM imidazole); F, fifth wash fraction (with 20 mM imidazole); G, elution fraction with 300mM Imidazole: H, purified D.RET6 after ion exchange chromatography.

Figure 13 is a silver-stained 12% SDS-polyacrylamide gel of D.RET6 overexpressed in insect cells. Lanes A and B shows purified D.RET6 as a monomer (25 kDa), dimer (50 kDa) and trimer (85 kDa) and lane C is after deglycosylation. Cleaved oligosaccharides were retained in the stacking gel and can be seen at the top of lane C. Excess PNGase-F appears as a band of approximately 30 kDa. Lane D shows the purified monomeric form of D.RET6.

Figure 14 shows Western blot detection of native histamine-binding protein in *Dermacentor reticulatus* salivary gland extract. Lane A, non-reduced form; lane B, reduced form; lane C, deglycosylated form.

Figure 15: Determination of the IC_{50} of three unlabeled competitors e.g. histamine, 1-methylhistamine, and 3-methylhistamine by generating a competitive binding curve of recombinant D.RET6. The graphically derived of IC_{50} of the unlabelled ligands above in displacing the radioactive histamine from the binding site by 50% are 133 nM, 750 μM and 365μM, respectively.

Figure 16 shows saturation curves of histamine binding in the absence (solid line) or presence (dashed lines) of serotonin. ♦no serotonin, ■2.4 μM and Δ 23.8 μM serotonin, respectively.

Figure 17: Radioactive histamine-binding assay of the recombinant D.RET6 in the absence (A) and presence of serotonin at 2.4 μM (B) and 23.8 μM (C).

Figure 18: Depiction of Histamine bound in the binding pocket of the histamine binding site of a cyclic peptide.

Figure 19: Three-dimensional depiction of Histamine bound in the binding pocket of the histamine binding site of a cyclic peptide.

Figure 20: (a) Ribbon diagram showing the arrangement of molecules A and B in the asymmetric unit of FS-HBP2. The 13 sheet is labelled A - I and α helices 1-3. The histamine ligands are shown as ball-and-stick representation, along with Tyr100. The arrow indicates the direction of view in (b) and the boxed region shows the portion enlarged in (c). (b) This view shows the helix and extended loop which occlude the barrel entrance. (c) Stereo view of the individual hydrogen bond contacts between residues in the A and B molecules. (d) Superposed C-α traces of molecules A and B [performed using SHP, (Stuart *et al.* 1979)].

Figure 21: Stereo views of the *H* (a), *L* (b) and *apo-L* (c) histamine binding sites, respectively. In each case the 2|Fo|-|Fc| map is displayed around the ligand. The figure shows the core structure of the protein (tube); contacting residues and secondary structure elements are labelled. In (c) the bound structure L (drawn transparent), has been superposed onto the apo coordinates.

Figure 22: An alignment of the cDNA-inferred amino acid sequences of the various HBPs, created using the pileup commands of the Genetics Computer Group. (1994). Program Manual for the Wisconsin Package, version 8. (575 Science Drive, Madison, Wisconsin, USA 53711).

EXAMPLES

Ticks

Ticks were reared according to Jones *et al.* (1988), as described in detail in co-pending International patent application PCT/GB97/01372, the contents of which are incorporated herein in their entirety.

The identification of proteins FS-HBP1, FS-HBP2, MS-HBP1 and D.RET6, and cloning of the encoding genes is also described in PCT/GB97/01372 (see Examples 1, 2, and 3).

The Ra-d0 (*Rhipicephalus appendiculatus*) library was constructed with mRNA from salivary glands of unfed *R. appendiculatus* ticks (127 males, 124 females). The Av-library (*Amblyomma variegatum*) was constructed with mRNA isolated from salivary glands of partially fed, adult *A. variegatum* ticks (50 males, fed for 6-7 days, and 50

females, fed for 4 to 5 days). The Ih/Bm library (a mixed *Ixodes hexagonus* and *Boophilus microplus* library) was constructed with the pooled mRNA from salivary glands of partially fed *Boophilus microplus* (30 females) and three-day fed *Ixodes hexagonus* ticks (20 males/20 females).

Example 1: Cloning and sequencing of the *Amblyomma variegatum*, *Ixodes hexagonus* and *Boophilus microplus* libraries

Using the RNAce Total Pure extraction kit (Bioline Ltd., UK), total RNA was isolated from salivary glands of partially fed *Amblyomma variegatum*, *Ixodes hexagonus* and *Boophilus microplus* ticks. The RNA samples were submitted to reverse-transcriptase polymerase chain reactions (RT-PCR), using the Titan One-Tube RT-PCR system (Boehringer Mannheim) and degenerate primers:

5'-AAYGGNGARCAYCARGAYGCNTGGAA; and

5'-KTRTMRTCNGTNRYCCANARYTCRTA, the design of which was based on conserved domains in the *Rhipicephalus appendiculatus* HBPs.

Cycling conditions were according to the manufacturer's suggestions, but a 48 °C annealing temperature was used. RT-PCR products were ligated into the pGEM-T vector (Promega), and partially sequenced, using the SP6 and T7 primer sites flanking the cloning site. Inserts of which the inferred amino-acid sequences showed similarity to the original *Rhipicephalus* HBPs were labeled with digoxygenin, using the High Prime DNA labeling kit (Boehringer Mannheim), and were used as probes to screen the libraries. An anti-digoxigenin antibody conjugated with alkaline-phosphatase was used to visualize probe hybridization. The Ra-d0 library was screened (according to Mierendorf et al.,1987) with serum from a guinea pig that had acquired resistance against *R. appendiculatus* ticks following repeated infestations.

The pBluescript SK (-) phagemids of positive clones were excised *in vivo*, using the R408 helper phage, as described by Short et al. (1988).

Example 2: Recombinant protein expression

Expression and purification of FS-HBP1, FS-HBP2, MS-HBP1 is described in detail in Example 3 of PCT/B97/01372.

1) Construction of clones for D.RET6

Using an *E. coli*-based expression system, the DNA sequence encoding D.RET6 (from Glu29 to Leu109) was subcloned as a *BclI/ Xho*I fragment into *BamH*I */Xho*I -digested pET-23 a (+) in the same reading frame as the 6x His tag using the PCR technique with the following primers, 5'-TATATGATCAGAAAACCCGCTCTGGG-3' and 5'TATA CTCGAGCCA GGGTTCGCCGT-3' (the enzyme recognition sites are underlined.). The recombinant plasmid was transformed into host strain AD494(DE3) pLysS, which uses the T7 system, and success of the procedure was confirmed by sequencing.

D.RET6 was also expressed in bacteria. The bacterial transformant was grown at 37°C in Luria-Bertani medium containing ampicillin and chloramphenicol. The culture was induced at its exponential growth phase (OD_{600} about 0.5) using 0.5-1 mM isopropyl β-D-thiogalactopyranoside (IPTG) and grown further for at least 4 hours before harvesting by centrifugation (4500xg, 4 °C, 5 mins.). The pellet was resuspended in the lysis buffer containing 6M urea, 20mM Tris pH8 and 500mM NaCl, sonicated briefly on ice, a few drops of Triton-X 100 added, and mixed by rolling at 4 °C for 5 mins. The supernatant was collected by centrifugation at 7500xg 4 °C for 30 mins.

D.RET6 was also expressed in the baculovirus expression system. The DNA fragment containing the complete coding sequence of D.RET6 was amplified using the oligonucleotides: 5'-TATGAAGATGCAGGTAGTGC-3' and:

5'-ATATGATCAGCCAGGGTTCGCCGT-3'.

The resulting PCR product was blunt-ended, digested with *BclI*, and ligated with the transfer vector pAcCL 29-1 -6xHis (Livingstone, 1989), which was prepared to have a blunt end at a *Sac* I site and an adhesive end at a *BamH*I site. The ligation product was then transferred into *E. coli* (XL1-Blue) and the transformant was grown to produce the plasmid. The plasmid was checked for the absence of any undesired mutations by complete resequencing. Sf9 cells were cotransfected at different ratios with the recombinant transfer vector and *Bsu36*I-cut *Autographa californica* polyhedrosis virus (BacPAK6) DNA in the presence of 8 μg of Lipofectin (Gibco BRL) per 24 μl reaction.

For expression, recombinant baculoviruses were identified as galactosidase-negative plaques by plating under Seaplaque agar. The putative recombinant clones were plaque purified once more. The clone from an infected Sf21 cell lysate that gave a positive result on a western blot using polyclonal anti-bacterial expressed D.RET6 antisera was

amplified and used in the production of the recombinant protein. For each subsequent production of the fusion protein, Sf9 cells were infected with these baculoviruses at MOI of about 5 and grown for 2-3 days before collecting the supernatant by centrifugation at 1000xg for 5 min. After 60% ammonium sulphate precipitation of the supernatant, the pellet was discarded. The pellet obtained at 100% ammonium sulphate precipitation was redissolved in Buffer A (50mM sodium phosphate, 300mM NaCl and 10% glycerol, pH8).

2) Protein purification and production of antisera

The purification steps were the same for both bacterial and baculovirus expression systems. Briefly, Ni^{2+}-nitrilo-triacetic acid resin, previously equilibrated in buffer A, was added to the supernatant or the solution. After incubation on a roller (2 hr 4 °C), the resin was transferred to a column and washed with 20 volumes of phosphate buffer (50mM sodium phosphate, 300mM NaCl and 10% glycerol, pH6.5). Protein was eluted with 5 volumes of 300mM Imidazole pH 8, concentrated, and the solvent replaced with phosphate-buffered saline using a Centricon-10 (Amicon) filtration unit. The recombinant D.RET6 was further purified on a HiTrap SP column (Pharmacia) using a gradient of 0.1-0.6 M NaCl in 50 mM MES pH 6.2.

To determine the location and solubility of the expressed protein in *E. coli*, the culture of the bacterial transformant was sampled before and 4 hours after IPTG-induction and processed according to the protocol described in the Qiaexpressionist booklet (QIAGEN). In brief, the sample was spun down, lysed by a cycle of freezing and thawing, and brief sonication, then centrifuged to separate insoluble proteins and the cytosolic soluble protein fraction. In another sampled culture, cells was pelleted and subjected to osmotic shock by, first, resuspending in 30mM Tris solution containing 20% sucrose (pH8) and incubating at room temperature with shaking in the presence of 1mM EDTA. The cells were then collected and resuspended in the low-osmotic ice-cold solution (5mM $MgSO_4$). The proteins released in the solution were collected by centrifugation. All fractions together with the pre-induced fraction were analysed by 12% SDS-PAGE.

Preparation of fusion proteins for antibody production and the technique for immunizing with small amounts of antigen are described by Sambrook *et al*, 1989. Briefly, guinea-pig anti-D.RET6 antiserum was prepared by repeated (x3)

intraperitoneal immunization of guinea pigs with homogenized 10% SDS-PAGE gel slices containing microgram quantities of bacterially-expressed purified D.RET6 in phosphate-buffered saline.

3) Electrophoresis and Western Blotting

SDS-PAGE gels and Western blots showing expression of FS-HBP1, FS-HBP2, MS-HBP1 is demonstrated in PCT/GB97/01372(see Figures 6 and 7).

Salivary glands (and other tissues) were excised from ticks at different time points of the feeding period, and homogenised in PBS. The homogenates were centrifuged at 10,000g for 5 minutes and the supernatants were submitted to sodium dodecyl sulphate-polyacrylamide electrophoresis (SDS-PAGE; Laemmli, 1970).

Figures 8 and 9 show the expression of D.RET6 in *E. coli* and insect cells, respectively.

For Western blotting, proteins were transferred to nitrocellulose (Gelman Sciences) by means of semi-dry electroblotting (Kyhse-Anderson, 1984) using an AE-6675 Horizblot MS-HBP1 from the first day p.a. until the end of the feeding period.

Figure 14 shows a Western blot showing expression of the D.RET6 protein.

4) Av-HBP protein expression and purification

The coding region of the Av-HBP cDNA was PCR amplified (95 °C for 30", 50 °C for 30", 72 °C for 30"; 18 cycles) using a forward primer designed to add a *Sac* I site upstream of the start codon (5'- TATGAGCTCATGAACTCTGCCTTGTGG; the *Sac*I site is underlined), and a reverse primer (5'- TATGGATCCGGGGTGGCCTCACCG) containing a *Bam*HI site (underlined). The product was ligated in between the *Sac* I and *Bam*HI sites of the pAcCl29.1 transfer vector (Livingstone and Jones, 1989) which had been modified by the insertion of six histidine codons and a stop codon, downstream of the *Bam*HI recognition site (see original patent). This resulted in the addition of the sequence Ile-$(His)_6$ to the carboxy- terminus of Av-HBP.

Co-transfection of Sf21 Spodoptera cells with the transfer vectors and baculovirus (BacPak6), and amplification of recombinant virus, were according to Kitts and Possee (1993). *Trichoplusia ni* cells (High Five, Invitrogen) and TC100 medium containing 10% foetal bovine serum (Gibco BRL) were used for protein expression. After 60 hours incubation at 28 °C, the secreted protein was precipitated from the medium with

ammonium sulphate (in the 45-80 % saturation fraction) and redissolved in a 50 mM sodium phosphate buffer (pH 8.0), containing 300 mM NaCl and 10% glycerol (buffer A). Talon beads (Clontech) were added to capture the oligohistidine-tagged proteins (1 hour incubation at 4°C). The beads were applied to a 10 ml-column, and washed with buffer A (20 volumes), then with 50 mM sodium phosphate buffer (pH 7.0), containing 300 mM NaCl and 10% glycerol (20 volumes), and finally with 50 mM sodium phosphate buffer (pH 7.0; 20 volumes). The protein was eluted using 200 mM imidazole in sodium phosphate buffer (100 mM, pH adjusted to 8.0).

Example 3: Characterisation of proteins

1) Histamine binding assays

The purified recombinant proteins were submitted to histamine binding assays as set out in Warlow and Bernard (1987). This method used protein precipitation to separate free from bound ligand (radiolabelled histamine) by addition of polyethylene glycol (molecular weight 8000) and centrifugation. In all experiments, thin-layer chromatographs were run in an acetate-ammonia solvent system after a four hour incubation period to ensure that no metabolisation of histamine had occurred.

Saturable binding of ^{3}H-histamine was obtained with FS-HBP1, FS-HBP2, MS-HBP1 rHBPs (see Figure 20 of PCT/GB97/01372).

For Av-HBP, semi-purified recombinant protein was incubated with varying amounts of tritiated histamine, and the amount of bound radiolabel was determined by liquid scintillation counting. Separation of free from bound ligand was obtained following the method described by Warlow and Bernard (1987), which uses polyethylene glycol (PEG 8000) to precipitate the protein. Results (not shown) suggested that the equilibrium dissociation constant (Kd) for histamine is around 7.3nM.

2) Radioligand binding assay for D.RET6

The recombinant D.RET6 was diluted with 1.5% γ-globulin (Sigma) and used in one set of experiments. Fifty microlitres of the protein solution were incubated with 50 µl of 1:2500 dilution of [2,5-^{3}H] histamine diHCl (1µCi/µl) solution (Amersham) at room temperature for at least 3 hours with or without increasing concentrations of unlabelled histamine. All the assays were carried out in a total volume of 200 µl. The incubations were terminated by adding 125 µl of PEG 8000 (36% w/v in PBS) and centrifuged in a

microfuge at maximum speed for 12 minutes to collect the bound protein. The tubes were spun once more to remove all supernatant without disturbing the pellets. Subsequently, pellets were redissolved in PBS. Three millilitres of liquid scintillation cocktail (Beckman) were added and the radioactivity measured using a liquid scintillation counter (Wallac, 1217 Rackbeta).

In a second set of experiments, a competitive binding assay was used to compare three unlabelled competitor ligands (histamine, 1-methylhistamine and 3-methylhistamine).

To study the effect of serotonin on histamine binding activity, 10 µl of PBS (as a control experiment) or 10 µl serotonin (50 µM or 500 µM) were added to each 200 µl binding assay.

For data analysis, the ligand affinity constant was estimated from Scatchard plots as previously described by Hulme, 1992, *Receptor-Ligand Interactions, IRL Press, Oxford*). The nonlinear regression was used to fit the data (Motulsky, 1987, *FASEB J*, **1:** 365-374) and two asymtotic straight lines were made as described elsewhere (Feldman, 1972, *Analytical Biochem* **48**: 317).

From the plotted curved line, two asymtotic straight lines were drawn according to Feldman (1972) consistent with two histamine binding sites of approximate Kd 6×10^{-8} M and 2×10^{-6} M. Comparison of the ability of histamine and its methylderivatives to displace radioactive histamine indicated that the binding by D.RET6 was specific for histamine (Figure 15). Surprisingly, the saturation curves and corresponding Scatchard plots for histamine binding in the presence of serotonin revealed a marked synergistic effect (Figures 15 and 16). At a final concentration of 2.38µM serotonin, the Kd for the two binding sites for histamine was 1.1×10^{-9} M and 1×10^{-6} M, and with 23.8µM serotonin, 1.3×10^{-9} M and 1×10^{-6} M, respectively.

Thus, in the presence of serotonin, the binding affinity of D.RET6 for its ligand, histamine, was found to increase sixty-fold. Recently, it has been reported that external stimuli (including serotonin) regulate mammalian H1 receptor activity, provoking increased ligand affinity (Bloemers, S. M., Verheule, S., Peppelenbosch, M. P., Smit, M. J., Tertoolen, L. G.J., and De Laat, S. (1998) *The Journal of Biological Chemistry* **273**(4), 2249-2255). Although the molecular details remain unclear, a conformational change in the H1 receptor, induced by serotonin, has been proposed to explain the

increase in affinity for histamine (Bloemers, 1998). It thus seems possible that the synergistic effect of serotonin on the tick histamine-binding protein has evolved to counteract serotonin-induced enhanced binding affinity of H1 receptors. Such a mechanism might therefore enable the tick protein to outcompete the host's serotonin-sensitized histamine receptors in the feeding site. As adult *D. reticulatus* feed on a variety of domestic and wild mammals, including dog, horse, cattle, sheep, deer, fox, hare and hedgehog, the synergistic effect of serotonin may provide flexibility in the performance of the tick's histamine-binding protein under a range of host-specific haemostatic responses.

This finding has important implications for the design of molecules with histamine binding activity and gives important insights into the mechanism of action of these tick proteins, along with molecules designed to mimic their action. For example, in order to alter the affinity of these molecules for histamine, serotonin may be delivered simultaneously in an appropriate amount.

Example 4: Crystallisation of proteins

Purified FS-HBP2 was dialysed against 10 mM histamine in water (the pH of the histamine solution was adjusted to 6.8 using NaOH), and concentrated using Centricon 10 centrifugation units (Amicon) to a final protein concentration of 20μg/μl. A hanging drop of 3μl of the protein/histamine solution combined with 2μl of mother liquor was allowed to equilibrate at room temperature with 1ml of mother liquor [0.1 M MES buffer (pH 6.5), containing 0.01 M cobalt chloride hexahydrate and 1.8 M ammonium sulphate (Hampton Research)].

Native data to 2.24Å resolution and derivative data to 3 Å were collected at room temperature using in-house Mar-research imaging plate detectors attached to Rigaku rotating anode generators. Frozen native and semi-apo data were collected (to 1 .24 Å and 1 .35 Å resolution respectively) at the Brookhaven National Laboratory synchrotron using a Brandeis single module CCD detector (see Table 1). The semi-apo crystal was prepared by immersion in several changes of histamine-free mother liquor during the week prior to data collection. Mother liquor containing 30% glycerol was used as a freezing solution. Crystals were kept at 100K using a cryostream (Oxford Cryosystems). Freezing resulted in a distinct change in unit cell dimensions, with axes b and c smaller

and axis a slightly larger than at room temperature. Diffraction data were processed with DENZO and SCALEPACK (Otwinowski and Minor, 1997).

Phasing and model building

The structure was solved by MIR using cis-platinum and trimethyllead-acetate (Holden and Rayment, 1991) derivatives (Table 1). Initially, 10-15° of data were collected for each new derivative. Data collection was continued only for crystals that showed appreciable isomorphous differences, otherwise they were transferred back to the mother liquor for the next soaking experiment.

Difference Patterson maps allowed two binding sites to be located, by inspection, for each heavy metal. Further sites and the common origin for the two derivatives were found by difference Fourier techniques. Trimethyllead-acetate introduces some degree of non-isomorphism (see Table 1). Data reduction, scaling and calculation of isomorphous differences were carried out with the in-house programs 3DSCALE and DIFFER (Stuart *et al.*, 1979). MIR-phases were calculated with MLPHARE (Otwinowski, 1991), and improved by solvent flattening with the program GAP (Grimes and Stuart, unpublished).

The initial maps revealed the presence of two molecules in the asymmetric unit. The noncrystallographic symmetry operator relating these molecules was determined and refined with GAP starting from the coordinates of the heavy metal binding sites and chosen marker positions from the electron density map. Non-crystallographic symmetry averaging resulted in an electron density map of high quality, which could be readily interpreted. Electron density map interpretation used FRODO (Jones, 1985) and 0 (Jones *et al.*, 1991).

TABLE 1

	Unit Cell (a,b,c)	Reso-lution (Å)	Total # reflect-ions	# Unique reflect-ions	Comp-leteness (%)	R-merge	% iso-morphous difference	# sites	Phasing power
Native 1	77.0,77.8,80.1	20-2.27	127,028	22,222	94.8	5.2	-	-	-
Cis Pt	76.9,77.8,80.1	20-3	35,045	9,898	97.6	8.0	20.5	6	1.6/1.3
TML	76.2,78.9,80.1	20-3	41,086	9,938	97.1	7.7	32.6	2	1.0/0.8

(a) Structure determination and refinement

	Native2	Apo
Unit cell (a,b,c)	77.5, 74.8, 78.6	77.5, 74.4, 77.9
Resolution range (Å)	20.0-1.24	20 – 1.35
No.of reflections	108,735	76,301
R-factor	18.4%	18.7%
No.of protein atoms	2744	2744
No.of water molecules	529	537
RMS bond length deviation	0.013Å	0.014Å
RMS bond angle deviation	1.5°	1.6°
Mean B-factor (Protein:A&B)	11Å^2	20^2
Mean B-factor (ligand, site *H*)	5Å^2	17Å^2
Mean B-factor (ligand, site *L*)	5Å^2	§
Mean B-factor (water)	26Å^2	36Å^2

(b) Refinement Statistics

Refinement and analysis

The initial map immediately revealed that FS-HBP2 had lipocalin topology. The coordinates for retinoic acid binding protein (IRBP) were used as an initial framework for model building. The initial model was refined against the room temperature dataset (Nativel, Table 1) using XPLOR (Brtinger, 1992) (rigid body, positional and B-factor refinement). The resulting model was refined against the higher resolution (Native2) data. Rigid body refinement yielded improved NCS operators which allowed positional B-factor and positional refinement to 1.24Å resolution. Further refinement included overall anisotropic B-factor refinement and simulated annealing. Water and histamine molecules were then included along with a bulk solvent correction. During the course of the refinement stereochemical restraints were modified so that eventually electrostatic and van der Waals terms were omitted from the target function.

PROCHECK (Laskowski *et al.*, 1993) was used for structure validation. Secondary structure assignments used DSSP (Kabsch and Sander, 1983). Structural superpositions

used SHP (Stuart *et al.*, 1979). Atomic coordinates used for comparisons were obtained from Protein Data Bank, Brookhaven National Laboratory.

Structure Determination of rFS-HBP2

The FS-HBP2-histamine complex crystallizes in an orthorhombic space group ($P2_12_12_1$) with 2 molecules per asymmetric unit. The unit cell dimensions vary, especially upon freezing (Table I). The structure was solved by the use of two heavy atom derivatives and refined using XPLOR (Brunger, 1992) to yield a final model with reasonable stereochemistry (RMS bond deviation 0.013 Å) and R-factor of 18.4%, for all data in the 20-1.24 Å resolution range (Table 1). 91.1 % of residues are within the most favoured region of the Ramachandran plot, no residues are in the disallowed region. The two crystallographically distinct molecules (A and B) are very similar (rms deviation for C~ atoms 0.6 Å). Significant differences are in loops at crystal contact points (Figure 20) (the sidechain conformation of residue Val21 also differs between the A and B molecules, but this is unlikely to affect biological function). Both molecules contain two histamines, bound at sites denoted H and L. The error in the co-ordinates for the majority of nonhydrogen atoms is less than 0.2 Å (Luzzatti, 1952).

The *A* and *B* molecules in the crystal have one extensive contact, main chain hydrogen bonds link a short strand following the α3-helix of molecule *A* (residues *A*143 to *A*146) to the end of strand B of molecule *B* (residues *B*54 to *B*57) (Figure 20a,c). Other hydrogen bonds link *A*150 ND2 to *B*25 0 and *A*167 OG to *B*59 OD 1. These molecules are not related by a two-fold axis. Several residues on the surface of the protein possess multiple conformations in the crystal, however these do not have a role in the structural and functional interactions discussed below. In line with the excellent diffraction, the crystallographic B-factors are rather low (Table 1), indicating that the molecule has a core of considerable rigidity. The refined model for molecule *A* consists of residues *A*1 - *A*171 of the native protein along with the engineered carboxyl-terminal Ile-(His)6 tag. Although the course of the polypeptide chain could be traced in this region, the positions of three of the His side chains was unclear and so they were modelled as Ala. No density was observed for the (His)6 tag in molecule *B* (residue *B*1 was also omitted due to disorder).

Overall Structure

The bulk of the molecule (approximate dimensions 33 Å x 38 Å x 45 Å) is an eight stranded anti-parallel β-barrel, whose topology places FS-HBP2 within the lipocalin superfamily (Figure 13 & Flower, 1996). Lipocalins are, typically, extracellular proteins which transport small hydrophobic ligands with varying degrees of specificity. The HBP β-barrel houses two histamine molecules and the protein is completed by partly helical amino-terminal and carboxyterminal extensions to the β-barrel (Figure 13a). From the high level of sequence similarity, we expect the overall structures of all three Ra-HBPs to be very similar (RMS deviation between Cα atoms ~1 Å).

Unique Features

Several features of functional significance set FS-HBP2 apart from other lipocalins.

The unusually extended amino terminus of FS-HBP2 initially runs along the barrel, forming hydrogen bond interactions with β-strands F and G before forming the α1 and α2 helix. The substantial α2 helix is positioned over the 'mouth' of the barrel, interacting with residues on the rim to form a significant barrier between the binding pockets and the exterior (Figure 20a,b). One side of the helix is held in place by hydrogen bonds to the loop joining strands B and C. The other side of the helix hydrogen bonds to strands F and G (the F-G loop is particularly prominent in HBPs, in line with a functional role).

As with other lipocalins there is an α3-helix, which abuts the mid-point of the barrel. In FS-HBP2, the helix is pinned to the barrel at its extremities by two disulphide bridges (Cys119 to Cysl48 and Cys48 to Cysl68).

Three structurally conserved regions (SCRs), lying in close proximity in the structure, have been identified as determinants of the lipocalin fold (Flower, 1996). SCRI includes a 3/10 helix followed by a Gly-X-Trp sequence in strand A. In FS-HBP2 an α-helix replaces the 3/10 helix and Asn-Val-Tyr (residues 27-29) replaces the signature sequence. In several lipocalins SCR2 contains a Thr-Asp-Tyr motif. Whilst FS-HBP2 does not have this signature sequence there are conformational similarities in this region (such as a characteristic kink in strand F). The final conserved region, between strand H and α3, contains an Arg or Lys residue, nearby the conserved Trp residue of SCRI. In HBP2 this loop contains the tripeptide Thr-Asp-Tyr (139-141), which is usually present in SCR2. Surprisingly, HBP2 contains several other elements of sequence that are also

reminiscent of misplaced lipocalin fragments (although the Glu-Lys-Val-Thr-Ala sequence in strand D is a perfect match with the equivalent portion of epididymal retinoic acid binding protein; Newcomer, 1993).

Perhaps the most striking unique feature of the HBP structure is the presence of the two ligand binding sites within the barrel core. One of the histamine molecules binds across the width of the binding pocket, requiring strands G and H to be stripped away from the rest of the sheet, distorting the canonical hydrogen bonding pattern.

Two Binding Sites which Differ in Affinity for Histamine

To dissect out the relative affinities of the two histamine binding sites, and probe the conformational implications of histamine binding, we attempted to remove histamine from preformed crystals. A rigorous regime of immersion of crystals in mother liquor (minus histamine) was followed by data collection at 100K. The diffraction data revealed that histamine was lost from one of the binding sites in both crystallographically independent molecules whilst the second site remained fully occupied. We infer from this that, in the crystal, one site has a far slower off-rate than the other. The similar behaviour of two molecules in different environments within the crystal strongly suggests that one site, termed H, has a higher intrinsic affinity than the other, termed L. The ligand-protein interactions observed support this assignment.

The binding sites are located, off-centre, at opposing ends of the barrel (Figure 20a). Unusually for a lipocalin (but in accord with the hydrophilic nature of the ligand) both binding pockets sequester a number of charged residues in the interior of the barrel. These residues are critical components of the histamine binding Sites (Figure 21a,b). The RMS difference in the length of the stabilizing hydrogen bonds between the A and B molecules is 0.08 Å; we therefore make no distinction between the two molecules in this respect. The side-chain of residue Tyr100 and a bridging water molecule form a wall separating the H and L sites. Nevertheless a hydrogen bond network links the two sites, the components of which are almost completely conserved between different HBPs. In the H site the histamine ligand lies perpendicular to the long axis of the barrel, leading to distortions in the structure of HBP, compared to other lipocalins. The aromatic side chains of Trp42 and Phe108 are arranged, parallel but slightly off-centre, to form strong Π-Π stacking interactions (McGaughey *et al.*, 1998) with the imidazole of the histamine molecule. The phenolic ring of Tyr100 is perpendicular to the plane of

the imidazole ring of the histamine, contributing further Π-Π interactions. There is an extensive network of hydrogen bonds between the nitrogen atoms of the histamine and the carboxylates of Glu (82 and 135) and Asp (39 and 110) residues, both directly and via bridging water molecules. From its environment, it is expected that the H-site histamine is bound in the di-cationic form.

In the L site the histamine molecule is parallel to the barrel with the imidazole moiety pointing toward the barrel centre. The types of interactions at the L site are similar to the H site but rather less favourable. The imidazole ring of the histamine has base stacking interactions with the phenolic ring of the Phe98 side chain, which are almost perpendicular. There are further van der Waals interactions with the phenolic ring of Tyr29 while Ser20, Asp24 OEl, Tyr100 OH and Aspl2O OE2 form hydrogen bonds with the histamine nitrogen atoms.

Tyr100 therefore has a role in binding both of the histamine molecules, albeit using different modes of interaction. No ordered water molecules are present in the L site and volume calculations suggest that the histamine is slightly less tightly packed in this site. B-factor analysis confirms, however that both histamine ligands are rigidly bound (Table I). The poorer fit of histamine in the L site, raises the question whether a compound other than histamine could be the natural ligand for this pocket.

Structure of FS-HBP2 with One Histamine Bound

The structure of FS-HBP2 without the histamine in the L site was determined in both molecule A and B, although in molecule B a remnant of histamine (approximately 10% occupancy) is seen. The model for this 'semi-apo' structure has an R-factor of 18.7% (Table 1). The structural details are essentially the same for molecule A and B. Four water molecules have replaced the histamine in the L site, one of which takes the position of the histamine Cβ atom (Figure 21c), whilst the others cushion destabilization by occupying the equivalent positions to the nitrogen atoms of the histamine. Removal of the histamine from the L site causes only slight of (of the order of a few tenths of an Angstrom; the overall RMS change in Cot positions is only 0.1 Å) and side chain conformations remain essentially unchanged, (Figure 21c). The histamine remains bound at full occupancy at the H site, consistent with a much higher affinity.

Implications of Sequence Variation within the HBP Family

Sequence variation amongst the three HBPs occurs even for residues directly involved in histamine binding, especially those contributing to the L pocket. Overall FS-HBP2 resembles FS-HBP1 more closely than MS-HBP1, however The L-pocket of FS-HBP2 is in fact more similar to that of MS-HBP1 than FS-HBPl, despite the fact that, overall, FS-HBP2 resembles FS-HBPl most strongly. In FS-HBP1, histidine and tyrosine residues replace Ser2O and Aspl2O, respectively. These changes must substantially modify both the shape and charge characteristics of the binding pocket. In contrast to the numerous changes in the L site, only the substitution of Phe 108 for a Leu impinges upon the H site of FS-HBP1. The Kds for FS-HBP2 and MS-HBP1 are similar, and about 10 times lower than that for FS-HBP1, suggesting that modifications at the L site modulate the observed binding affinities. Modelling the FS-HBPI structure indicates that the loss of aromatic residues may open up an internal cavity, presumably changing the specificity.

MS-HBP3, the male specific protein, has more substantial changes compared to FS-HBP2, including insertions and deletions in the loop regions. MS-HBP1 contains an additional Cys (150), which is likely to be on the surface of the molecule and may be responsible for the formation of the covalent dimers discussed above. The putative glycosylation site, Asn6l is also likely to be exposed to the solvent (Figure 13).

Example 5: Design of a synthetic cyclic peptide with histamine binding activity

There are two chains in the histamine binding proteins identified in Figures 17 and 18, A and B. Each chain binds two histamines, one in μmol and one in ρmol quantities. Geometrical investigation of the four binding sites is summarised in Tables 2 and 3 below.

These data indicate that in the ρmol binding pockets the positively charged quaternary nitrogen tail of histamine is bound to two negatively charged residues (Asp 110 and Glu 135). Similarly, the positively charged imidazole ring is bound to two negatively charged residues (Glu 82 and Asp 39), through the two nitrogens of the ring. There are also two aromatic ring to positive charge interactions between the imidazole ring nitrogen and Trp 42 and Phe 108.

1) Peptide Design

The analysis of the active sites suggested that in order to mimic the histamine binding

sites two separate types of interaction need be considered. The first type of interaction is that between the positively charged centres (nitrogen tail and imidazole ring) and negatively charged residues. The second interaction type being between the positively charged imidazole ring and an aromatic ring.

This led to the design of several cyclic peptide systems incorporating negatively charged residues, e.g. Glu, and aromatic residues e.g. Phe. Initial modelling studies indicated that cyclic hexapeptides would not be sufficiently flexible to allow for histamine recognition. Modelling of cyclic octapeptide systems indicates that they will potentially allow for histamine binding.

The sequence for the suggested cyclic octapeptide is:

Ala-Glu-Ala-Phe-Ala-Glu-Ala-Trp

Figures 17 and 18 show a minimised conformation of the cyclic octapeptide / histamine system. These figures reveal the suggested mode of binding between the histamine and the cyclic peptide. At either 'end' of the cyclic peptide are two negatively-charged Glu residues to interact with the positively charged nitrogen tail and the imidazole ring. The Phe and Trp residues at opposing sides of the imidazole ring allow for aromatic–positive charge interaction.

The interaction distances between the different centres (positive charge to negative charge and positive charge to aromatic group) are shown in Table 2.

Table 2. Average Hst – Peptide Distances

Interaction	Distance Å
Hst Tail -- Glu Acid C	3.66
Imidazole ring – Glu Acid C	3.53
Imidazole ring – Phe Centroid	4.91
Imidazole ring – Trp Centroid	4.94

Atom Numbering System.

Table 3. Strong Binding Sites

Hst Atom	Residue	Atom	A-Chain Å	B-Chain Å
1	Tyr 36	OH	3.32	3.4
1	Asp 110	Acid C	3.67	3.66
1	Glu 135	"	3.88	3.84
2	Glu 82	"	3.33	3.37
3	Asp 39	"	3.44	3.35
3	Trp 42	Centroid of Ring	3.7	3.97
3	Phe 108	"	4.1	4.21

Table 4. Hst Weak Binding Sites

Hst Atom	Residue	Atom	A-Chain Å	B-Chain Å
1	Ser 20	C=O	2.85	2.83
1	Ser 20	OH	3.07	3.13
1	Asp 24	Acid C	2.88	3.12
1	Tyr 29	Centroid	3.23	3.21
1	Asp 120	O	3.64	2.71
2	Asp 24	O	2.64	2.66
3	Tyr 100	OH	2.80	2.78

REFERENCES

Blake, M.S., Johnston, K.H., Russell-Jones, G.J., Gotschlich, E.C. (1984) A rapid, sensitive method for detection of alkaline-phosphatase-conjugated anti-antibody on Western blots. *Anal. Biochem.* **136**, 175-179.

D.M. Glover, ed., *DNA cloning: a practical approach, Volume II: Expression systems*, (IRL Press, 1995).

D.M. Glover, ed., *DNA cloning: a practical approach, Volume IV: Mammalian systems*, (IRL Press, 1995).

Falus A. (1994) Histamine and Inflammation, R.G. Landes Company, Austin, 139.

Gantz I., DelValle J., Wang L-d., Tashiro T., Munzert T., Guo Y-J., Konda Y. and Yamada T. (1992) *J. Biol. Chem.* **267**, 20840-20843.

Goode, B.L. and Feinstein, S.C. (1992) "Speedprep" purification of template for double-stranded DNA sequencing. *Bio Techniques* **12**, 374-375.

Hogan J.C. (1997) *Nature Biotech.* **15**, 328-330.

Holden H.M. and Rayment I. (1991) *Archives of Biochemistry and Biophysics* **291**, 187-194.

Janknecht R., de Martynoff G., Lou L., Hipskind R.A., Nordheim A. and Stunnenberg H.G. (1991) Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus. *PNAS USA* **88**, 8972-8976.

Jones L.D., Davies C.R., Steele G.M. and Nuttall P.A. (1988). The rearing and maintenance of Ixodid and Argasid ticks in the laboratory. *Animal Technology* **39**, 99-106.

Kitts P.A. and Possee R.D. (1993) A method for producing recombinant baculovirus expression vectors at high frequency. *BioTechniques* **14**, 810-817.

Kyhse-Anderson J. (1984) Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. *J. Biochem. Biophys. Methods* **10**, 203-209.

Laemmli V.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **277**, 680-685.

Livingstone C. and Jones I. (1989) Baculovirus expression vectors with single strand capability. *Nucleic Acids Res.* **17**, 2366.

Maley F., Trimble R.B., Tarentino A.L. and Plummer T.H. Jr. (1989) Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases. *Anal. Biochem.* **180**, 195-204.

Matsudaira P. (1987). Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. *J.Biol. Chem.* **262**, 10035-10038.

Mierendorf R.C. and Pfeffer D. (1987) Direct sequencing of denatured plasmid DNA. *Methods Enzymol.* **152**, 556-562.

O'Reilly *et al.*, (1994) *Baculovirus expression vectors - a laboratory manual*, Oxford University Press.

Program Manual for the Wisconsin Package, version 8 (1994) Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711.

Protein Expression in Current Protocols in Molecular Biology (Chapter 16). Editors : F.M. Ausubel, R. Brent, R.E. Kingson, D.D. Moore, J.G. Seidman, J.A. Smith, K. Struhl. Published by John Wiley and Sons, Inc.

Rees A.R. *et al.*, eds, *Protein Engineering: A practical approach,* IRL Press 1993.

Ribeiro J.M. and Walker F.A. (1994) High-affinity histamine-binding and antihistaminic activity of the salivary nitric oxide-carrying heme protein (nitrophorin) of Rhodnius prolixus. *J. Exp. Med.* **180**, 2251-2257.

Sambrook J., Fritsch E.F. and Maniatis T. (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbour Laboratory.

Sanger F. and Coulson A.R. (1975). A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. *J.Mol. Biol.* **94**, 441-448.

Schägger, H. and von Jagow, G. (1987) Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100kDa. *Anal. Biochem.* **166**, 368-379.

Short J.M., Fernandez J.M., Sorge J.A. and Juse W.D. (1988) λZAP: a bacteriophage λ expression vector with *in vivo* excision properties. *Nucl. Acids Res.* **16**, 7583-7600.

Towbin, H., Staeholin, T. and Gordon, J. (1979) Electrophoretic transfer of proteins from polyacrylamid gels to nitrocellulose sheets : Procedure and some applications. *Proc. Natl. Acad. Sci. USA* **76**, 4350-4354.

Wang H. and Nuttal P.A. (1995). Immunoglobulin G binding proteins in male *Rhipicephalus appendiculatus* ticks. *Parasite Immunology* **17**, 517-524.

Warlow R.S. and Bernard C.C.A. (1987). Solubilization and characterization of moderate and high affinity histamine binding sites on human blood mononuclear cells. *Molec. Immun.* **24**, 27-37.

Watson *et al.*, Recombinant DNA (2nd edition), Scientific American Books.

CLAIMS

1. A histamine or serotonin binding compound capable of binding to histamine or serotonin with a dissociation constant of less than 10^{-7}M and which has a binding site comprising amino acid residues phenylalanine, isoleucine or leucine at position I, tryptophan at position II and aspartate or glutamate at positions III and IV wherein residues I to IV are positioned substantially the same as residues 108, 42, 39 and 82 respectively in either of Figures 1 or 2, or residues 107, 41, 38 and 78 in Figure 3 or residues 122, 54, 50 and 95 in Figure 4, and functional equivalents thereof, wherein the numbering of the amino acid residues refers to the sequence of the mature protein that lacks the leader sequence.

2. A histamine or serotonin binding compound capable of binding to histamine or serotonin with a dissociation constant of less than 10^{-7}M and which has a binding site comprising amino acid residues phenylalanine or isoleucine at residue I, tryptophan at residue II and aspartate or glutamate at residues III and IV wherein residues I to IV are positioned substantially the same as residues 98, 137, 24 and 120 respectively in either of Figures 1 or 2, or residues 95, 138, 23 and 120 in Figure 3 or residues 112, 149, 35 and 135 in Figure 4, and functional equivalents thereof, wherein the numbering of the amino acid residues refers to the sequence of the mature protein that lacks the leader sequence.

3. A histamine binding compound capable of binding to histamine or serotonin with a dissociation constant of less than 10^{-7}M and which has two binding sites, the first binding site comprising amino acid residues phenylalanine, isoleucine or leucine at position I, tryptophan at position II and aspartate or glutamate at positions III and IV wherein residues I to IV are positioned substantially the same as residues 108, 42, 39 and 82 respectively in either of Figures 1 or 2, or residues 107, 41, 38 and 78 in Figure 3 or residues 122, 54, 50 and 95 in Figure 4, and the second binding site comprising amino acid residues phenylalanine or isoleucine at residue I, tryptophan at residue II and aspartate or glutamate at residues III and IV wherein residues I to IV are positioned substantially the same as residues 98, 137, 24 and 120 respectively in either of Figures 1 or 2, or residues 95, 138, 23 and 120 in Figure 3 or residues 112, 149, 35 and 135 in Figure 4, and functional equivalents thereof, wherein the

numbering of the amino acid residues refers to the sequence of the mature protein that lacks the leader sequence.

4. A histamine binding or serotonin binding compound according to claim 1 or 3 additionally comprising at residue V, a tyrosine residue, wherein residue V is positioned substantially the same as residue 100 in the sequence of either of Figures 1 or 2, residue 97 in Figure 3 or residue 114 in Figure 4, and functional equivalents thereof, wherein the numbering of the amino acid residues refers to the sequence of the mature protein that lacks the leader sequence.

5. A histamine or serotonin binding compound according to claim 2 or 3 additionally comprising at residue V, a tyrosine residue, wherein residue V is positioned substantially the same as residue 29 in the protein sequence of either of Figures 1 or 2, residue 28 in Figure 3 or residue 40 in Figure 4, and functional equivalents thereof, wherein the numbering of the amino acid residues refers to the sequence of the mature protein that lacks the leader sequence.

6. A histamine or serotonin binding compound according to any preceding claim wherein said compound is stabilised by either or both of the disulphide bridges formed between cysteines 48 and 169 and cysteines 148 and 119 in the protein sequence of either of Figures 1 or 2, cysteines 47 and 175 and cysteines 151 and 119 of Figure 3 or cysteines 162 and 134 of Figure 4, wherein the numbering of the amino acid residues refers to the sequence of the mature protein that lacks the leader sequence.

7. A histamine or serotonin binding compound of any one of the preceding claims which comprises a peptide, or a fragment of any one of the proteins whose amino acid sequences are presented in Figures 1-4.

8. The histamine or serotonin binding compound of claim 7 that comprises a cyclic peptide.

9. The histamine or serotonin binding compound of claim 8 wherein said cyclic peptide comprises the sequence Ala-Glu-Ala-Phe-Ala-Glu-Ala-Trp.

10. The histamine or serotonin binding compound of any one of claims 1 to 9 that comprises a synthetic compound.

11. A protein comprising the Ra-Res amino acid sequence given in Figure 5 or functionally equivalent derivative or functionally equivalent fragment thereof.

12. A protein comprising the Av-HBP amino acid sequence given in Figure 6 or functionally equivalent derivative or functionally equivalent fragment thereof.

13. A protein comprising the Ih/Bm-HBP1 amino acid sequence given in Figure 7 or functional equivalent derivative or fragment thereof.

14. A protein comprising the Ih/Bm-HBP2 amino acid sequence given in Figure 8 or functional equivalent derivative or fragment thereof.

15. A protein comprising the Ih/Bm-HBP3 amino acid sequence given in Figure 9 or functional equivalent derivative or fragment thereof.

16. A protein comprising the Ih/Bm-HBP4 amino acid sequence given in Figure 10 or functional equivalent derivative or fragment thereof.

17. A protein comprising the Ih/Bm-HBP5 amino acid sequence given in Figure 11 or functional equivalent derivative or fragment thereof.

18. The histamine or serotonin binding compound of any one of claims 1 to 10 or protein according to any one of claims 11 to 17 produced by recombinant DNA technology.

19. A histamine or serotonin binding compound or protein according to any one of the preceding claims that binds specifically to histamine.

20. The histamine or serotonin binding compound or protein of any one of the preceding claims having an effector or reporter molecule attached thereto.

21. The histamine or serotonin binding compound or protein of any preceding claim that is derived from blood-feeding ectoparasites, spiders, scorpions or snakes and venomous animals.

22. The histamine or serotonin binding compound or protein of claim 21 that is derived from ticks.

23. The histamine or serotonin binding compound or protein of claim 22 that is derived from Ixodid ticks.

24. The histamine or serotonin binding compound or protein of claim 23 that is derived from *Rhipicephalus appendiculatus, D. reticulatus, Amblyomma variegatum, Boophilus microplus or Ixodes hexagonus.*

25. The histamine or serotonin binding compound or protein of any one of the preceding claims associated with one or more carbohydrate moieties.

26. The histamine or serotonin binding compound or protein of any one of the preceding claims that is associated with one or more peptides or polypeptides.

27. The histamine or serotonin binding compound or protein of claim 26 that is genetically or chemically fused to one or more peptides or polypeptides.

28. The histamine or serotonin binding compound or protein of any one of the preceding claims attached to a label or toxin.

29. The histamine or serotonin binding compound or protein of any one of the preceding claims that is bound to a support, such as a resin.

30. A therapeutic or diagnostic composition comprising a histamine or serotonin binding compound or protein according to any one of the preceding claims.

31. A therapeutic or diagnostic composition according to claim 30 additionally comprising serotonin.

32. A therapeutic or diagnostic composition according to claim 31 additionally comprising a cysteinyl leukotriene, platelet activating factor, or a thromboxane.

33. A vaccine comprising a histamine or serotonin binding compound according to any one of claims 1-10 or protein according to any one of claims 11-17.

34. The histamine or serotonin binding compound or protein according to any one of claims 1 to 29 or composition of any one of claims 30 to 32 for use in therapy.

35. The histamine or serotonin binding compound or protein according to any one of claims 1 to 29 for use as a pharmaceutical.

36. Use of the histamine or serotonin binding compound or protein according to any one of claims 1 to 29 as a pharmaceutical.

37. The histamine or serotonin binding compound or protein according to any one of claims 1 to 29 for use in a vaccine.

38. Use of the histamine or serotonin binding compound or protein according to any one of claims 1 to 29 in a vaccine.

39. The histamine or serotonin binding compound or protein of any one of claims 1 to 29 for use in the detection or quantification of histamine in human, animal, plant, and food material

40. The histamine or serotonin binding compound of any one of claims 1 to 29 for use in the depletion or removal of histamine from food products, cell cultures or human, animal, plant and food material.

41. The histamine or serotonin binding compound of any one of claims 1 to 29 for use in the binding or detection of histamine in humans or animals.

42. The histamine or serotonin binding compound or protein of any one of claims 1 to 29 for use as an anti-histamine agent, an anti-inflammatory drug or in the treatment of allergy.

43. The histamine or serotonin binding compound or protein of any one of claims 1 to 29 for use as a tool in scientific research concerning the role of histamine in biological processes.

44. The use of a histamine or serotonin binding compound according to any one of claims 1 to 29 in conjunction with a pharmaceutically-acceptable carrier in the manufacture of a medicament for the treatment or prevention of inflammation or allergic reaction in humans or animals.

45. A nucleic acid compound which encodes a histamine or serotonin binding molecule or protein according to any one of claims 1 to 29 or which hybridises with said nucleic acid molecule under standard hybridisation conditions.

46. The nucleic acid molecule of claim 45 which comprises DNA, cDNA or RNA.

47. A cloning or expression vector comprising a nucleic acid molecule according to either of claims 45 or 46.

48. The vector of claim 47 which is virus based.

49. A host cell transformed or transfected with the vector of either of claims 47 or 48.

50. A transgenic animal that has been transformed by a nucleic acid molecule according to either of claims 45 or 46 or vector according to either of claims 47 or 48.

FIG. 1

FS-HBP1

```
T3→
   1  AGAAAGCCAACATGAAGCTTCTGCTCTCTCTTGCCTTCGTCTTAGCTCTCAGCCAAGTTA   60
                M  K  L  L  L  S  L  A  F  V  L  A  L  S  Q  V  K

  61  AAGCCGATAAGCCAGTTTGGGCGGATGAAGCGGCAAACGGGGAACACCAAGACGCCTGGA  120
       A  D  K  P  V  W  A  D  E  A  A  N  G  E  H  Q  D  A  W  K
          ↑

 121  AGCATCTCCAAAAACTCGTTGAAGAGAATTACGACTTGATAAAAGCCACCTACAAGAACG  180
        H  L  Q  K  L  V  E  E  N  Y  D  L  I  K  A  T  Y  K  N  D

                                          T3a→  ←T7c
 181  ACCCAGTTTGGGGTAACGACTTCACTTGCGTGGGTACTGCAGCGCAGAATTTGAACGAGG  240
        P  V  W  G  N  D  F  T  C  V  G  T  A  A  Q  N  L  N  E  D

 241  ACGAGAAGAACGTTGAAGCATGGTTTATGTTTATGAATAATGCTGATACCGTATACCAAC  300
        E  K  N  V  E  A  W  F  M  F  M  N  N  A  D  T  V  Y  Q  H

 301  ATACTTTTGAAAAGGCGACTCCTGATAAAATGTACGGTTACAATAAGGAAAACGCCATCA  360
        T  F  E  K  A  T  P  D  K  M  Y  G  Y  N  K  E  N  A  I  T

 361  CATATCAAACAGAGGATGGGCAAGTTCTCACAGACGTCCTTGCATTCTCTGACGACAATT  420
        Y  Q  T  E  D  G  Q  V  L  T  D  V  L  A  F  S  D  D  N  C

 421  GCTATGTCATCTACGCTCTTGGCCCAGATGGAAGTGGAGCAGGTTACGAACTCTGGGCTA  480
        Y  V  I  Y  A  L  G  P  D  G  S  G  A  G  Y  E  L  W  A  T

                                T3b→  ←T7d
 481  CCGATTACACGGATGTTCCAGCCAGTTGTCTAGAGAAGTTCAATGAGTATGCTGCAGGTC  540
        D  Y  T  D  V  P  A  S  C  L  E  K  F  N  E  Y  A  A  G  L

 541  TGCCGGTACGGGACGTATACACAAGTGATTGCCTCCCAGAATAACTTGGGCATATCGTAA  600
        P  V  R  D  V  Y  T  S  D  C  L  P  E  *

 601  TTTCAACTTCAAAGTGTGTTATTGTCAGCATATGTCTCGAGTGTTTGATGTAGTGCGTTC  660

 661  GATGATGCCATTCATCTAGGTTTCGGGTGTTCGGTACTTTATGGTCACTGCCGACGGCCA  720

                                                          ←T7
 721  GCACGAGTACTCGAAAATAAAGTATTCTGAAATCGGAAAAAAAAAAAAAAA  770
```

FIG. 2

FS-HBP2

```
T3→
   1  GCCGCGACGGAACTTCGAAGGAAGTCAGCATGAAGCTTCTCATACTCTCTCTTGCCCTCG   60
                                  M  K  L  L  I  L  S  L  A  L  V

  61  TCCTCGCCCTCAGCCAGGTTAAGGGAAATCAGCCAGATTGGGCCGATGAAGCGGCAAATG  120
      L  A  L  S  Q  V  K  G  N  Q  P  D  W  A  D  E  A  A  N  G
                                ↑

 121  GTGCACACCAAGACGCCTGGAAGAGTCTGAAAGCGGACGTTGAAAACGTTTACTACATGG  180
      A  H  Q  D  A  W  K  S  L  K  A  D  V  E  N  V  Y  Y  M  V

 181  TGAAGGCCACCTATAAGAATGACCCAGTGTGGGGCAATGACTTCACTTGCGTGGGTGTTA  240
      K  A  T  Y  K  N  D  P  V  W  G  N  D  F  T  C  V  G  V  M

                T3b→  ←T7a
 241  TGGCAAATGATGTCAACGAGGATGAGAAGAGCATTCAAGCAGAGTTTTTGTTTATGAATA  300
      A  N  D  V  N  E  D  E  K  S  I  Q  A  E  F  L  F  M  N  N

 301  ATGCTGACACAAACATGCAATTCGCCACTGAAAAGGTGACTGCTGTTAAAATGTATGGTT  360
      A  D  T  N  M  Q  F  A  T  E  K  V  T  A  V  K  M  Y  G  Y

 361  ACAATAGGGAAAACGCCTTCAGATACGAGACGGAGGATGGCCAAGTTTTCACAGACGTCA  420
      N  R  E  N  A  F  R  Y  E  T  E  D  G  Q  V  F  T  D  V  I

                                                    →
 421  TTGCATACTCTGATGACAACTGCGATGTCATCTACGTTCCTGGCACAGACGGAAATGAGG  480
      A  Y  S  D  D  N  C  D  V  I  Y  V  P  G  T  D  G  N  E  E

                ←
 481  AAGGTTACGAACTATGGACTACGGATTACGACAACATTCCAGCCAATTGTTTAAATAAGT  540
      G  Y  E  L  W  T  T  D  Y  D  N  I  P  A  N  C  L  N  K  F

 541  TTAATGAGTACGCTGTAGGTAGGGAGACAAGGGATGTATTCACAAGTGCTTGCCTAGAGT  600
      N  E  Y  A  V  G  R  E  T  R  D  V  F  T  S  A  C  L  E  *

            →                                   ←
 601  AATAACTTCAGAATGTCGTTCTTTCAAAGCGAAAAACCAACAATGTGAACATCGGCTTGC  660

 661  TGTGCTCGACGTAGCCAGCGATAATGTTGTTTTCCTGGGTTTCTGGGTTTGGATACTTTT  720

 721  AGCCACTGCCGAAGAGCTGTAAAGGTAATGAAAAATAAAATGTTCAAGAGTGTGAAAAAA  780

                ←T7
 781  AAAAAAAAAAAAA  793
```

FIG. 3

MS-HBP1

```
      T3→
1     AAAGCACTCAACATGAAGGTTCTTTTGTTGGTTCTTGGAGCTGCTCTTTGCCAGAATGCA   60
                M  K  V  L  L  L  V  L  G  A  A  L  C  Q  N  A

61    GATGCAAACCCAACATGGGCGAACGAAGCTAAATTGGGATCCTACCAAGACGCCTGGAAG   120
      D  A  N  P  T  W  A  N  E  A  K  L  G  S  Y  Q  D  A  W  K
            ↑

121   AGCCTTCAGCAAGACCAAAACAAGAGATACTATTTGGCACAAGCGACACAAACGACTGAC   180
      S  L  Q  Q  D  Q  N  K  R  Y  Y  L  A  Q  A  T  Q  T  T  D

                                  →
181   GGCGTATGGGGTGAAGAGTTTACTTGTGTGAGTGTTACGGCTGAGAAGATTGGAAAGAAA   240
      G  V  W  G  E  E  F  T  C  V  S  V  T  A  E  K  I  G  K  K

            ←
241   AAACTTAACGCTACGATCCTCTATAAAAATAAGCACCTTACTGACCTGAAAGAGAGTCAT   300
      K  L  N  A  T  I  L  Y  K  N  K  H  L  T  D  L  K  E  S  H
               ═══

301   GAAACAATCACTGTCTGGAAAGCATACGACTACACAACGGAGAATGGCATCAAGTACGAG   360
      E  T  I  T  V  W  K  A  Y  D  Y  T  T  E  N  G  I  K  Y  E

361   ACGCAAGGGACAAGGACGCAGACTTTCGAAGATGTCTTTGTATTCTCTGATTACAAGAAC   420
      T  Q  G  T  R  T  Q  T  F  E  D  V  F  V  F  S  D  Y  K  N

                  →                                     ←
421   TGCGATGTAATTTTCGTTCCCAAAGAGAGAGGAAGCGACGAGGGCGACTATGAATTGTGG   480
      C  D  V  I  F  V  P  K  E  R  G  S  D  E  G  D  Y  E  L  W

481   GTTAGTGAAGACAAGATTGACAAGATTCCCGATTGCTGCAAGTTTACGATGGCGTACTTT   540
      V  S  E  D  K  I  D  K  I  P  D  C  C  K  F  T  M  A  Y  F

                     →
541   GCCCAACAGCAGGAGAAGACGGTTCGTAATGTATACACTGACTCATCATGCAAACCAGCA   600
      A  Q  Q  Q  E  K  T  V  R  N  V  Y  T  D  S  S  C  K  P  A

601   CCAGCTCAGAACTGATATTCTGGTAATGCTTGAACCGTAATGGTTCGACCTGCAGTCTAG   660
      P  A  Q  N  *

661   AAACATTTACCACCATCACGGTGATTATCTTACCGTAGTTTCTTAGGTCTTGTTCTTTGA   720

                                                  ←T7
721   ATAAAATAGTTCCCTGCATTGACAAAAAAAAAA  753
```

FIG. 4

```
T3→
   1  ATGAAGATGCAGGTAGTGCTCTTACTTACCTTTGTTAGCGCCGCCCTCGCCACTCAAGCG   60
   1  M  K  M  Q  V  V  L  L  L  T  F  V  S  A  A  L  A  T  Q  A    20

  61  GAGACTACATCTGCGAAAGCAGGAGAAAACCCGCTCTGGGCGCATGAGGAACTACTTGGA  120
  21  E  T  T  S  A  K  A  G  E  N  P  L  W  A  H  E  E  L  L  G    40
                              ↑

 121  AAATATCAAGATGCCTGGAAAAGCATCGATCAGGGCGTGTCGGTGACTTATGTCCTTGCA  180
  41  K  Y  Q  D  A  W  K  S  I  D  Q  G  V  S  V  T  Y  V  L  A    60

                                 →                    ←
 181  AAGACAACATATGAGAATGACACAGGATCATGGGGATCCCAGTTTAAGTGCCTCCAGGTA  240
  61  K  T  T  Y  E  N  D  T  G  S  W  G  S  Q  F  K  C  L  Q  V    80

 241  CAAGAAATAGAAAGAAAGGAAGAAGACTATACAGTTACATCTGTTTTCACCTTTAGAAAT  300
  81  Q  E  I  E  R  K  E  E  D  Y  T  V  T  S  V  F  T  F  R  N   100

 301  GCGTCTTCTCCAATCAAGTATTACAACGTGACAGAAACAGTGAAGGCCGTTTTTCAATAT  360
 101  A  S  S  P  I  K  Y  Y  N  V  T  E  T  V  K  A  V  F  Q  Y   120

 361  GGATACAAAAACATAAGGAATGCAATTGAATACCAAGTGGGCGGTGGACTTAACATAACC  420
 121  G  Y  K  N  I  R  N  A  I  E  Y  Q  V  G  G  G  L  N  I  T   140

                                 →     ←
 421  GACACGCTCATTTTCACTGATGGAGAATTATGCGATGTTTTCTATGTTCCCAATGCAGAT  480
 141  D  T  L  I  F  T  D  G  E  L  C  D  V  F  Y  V  P  N  A  D   160

 481  CAAGGTTGTGAGCTCTGGGTCAAAAAGAGTCACTACAAACACGTACCAGACTACTGCACG  540
 161  Q  G  C  E  L  W  V  K  K  S  H  Y  K  H  V  P  D  Y  C  T   180

 541  TTCGTGTTCAATGTTTTCTGTGCGAAAGACAGGAAAACCTACGATATATTTAATGAAGAA  600
 181  F  V  F  N  V  F  C  A  K  D  R  K  T  Y  D  I  F  N  E  E   200

 601  TGTGTTTATAACGGCGAACCCTGGCTTTAAAGGCAAAAAATCTATAAAATACGGTTTCTG  660
 201  C  V  Y  N  G  E  P  W  L  *                                  220

                                                                ←T7
 661  TAGTAAGTACTAATAGCAAGTAGTTGAATAATAAAAAGATTGTAAGTGCAAAAAAAAAA  719
```

FIG. 5

Ra-Res

```
1   CAACTGATCACTAAAATGTTCCTTGCGGGTTTCTTCATTTTCGGCGCTGCCGTCCTCTCA   60
                M  F  L  A  G  F  F  I  F  G  A  A  V  L  S

61  GTTTTGGCTGAGGAGACACCTAATGATAGATGTACTACACACACTCCTAATGGATGGCAG   120
    V  L  A  E  E  T  P  N  D  R  C  T  T  H  T  P  N  G  W  Q

121 TTTCTCAAGAAAGGCAAGAGATACGATATGAAACAGAGAACCTTCCAAACACCTAACTCA   180
    F  L  K  K  G  K  R  Y  D  M  K  Q  R  T  F  Q  T  P  N  S

181 GACGACACTAAATGCCTGTCCAGTACTATCGACGGAAAGAATGAAAATAACCATACAGTA   240
    D  D  T  K  C  L  S  S  T  I  D  G  K  N  E  N  N  H  T  V

241 CAAGCAACGATAAGATATCGAAATGGTTATGAAGGAAAATGGGACACCATCCGCCAGGAG   300
    Q  A  T  I  R  Y  R  N  G  Y  E  G  K  W  D  T  I  R  Q  E

301 TACGAGTTCCCCAACTACACTGCAGGAGACTACAACTCCATGAAGACAACAGACAAATCC   360
    Y  E  F  P  N  Y  T  A  G  D  Y  N  S  M  K  T  T  D  K  S

361 CCGCCTCCGCCGGCATCATACCTGTTTGGATATACTGGAAGCTCTTGTGCCGTGGTGTAC   420
    P  P  P  P  A  S  Y  L  F  G  Y  T  G  S  S  C  A  V  V  Y

421 GTGAATTCCATTGGACCTGTTCGTAGCAATTCTGAAAACCCACCAGAAAGACTCACAGCA   480
    V  N  S  I  G  P  V  R  S  N  S  E  N  P  P  E  R  L  T  A

481 AGTCAGGAAAGTGCACAACGCGATTGCGTCCTTTGGGTCGATCACGATGAAAAAGCTACC   540
    S  Q  E  S  A  Q  R  D  C  V  L  W  V  D  H  D  E  K  A  T


541 CAAGAACAATGCTGTGAAGATTTCTTCAAGACCCACTGCAAAGAGACTGTCCATGTCATA   600
    Q  E  Q  C  C  E  D  F  F  K  T  H  C  K  E  T  V  H  V  I

601 TACGACGTGAATAGATGCAAGGAGAATGGCAGTGAATAACACGATGCCGGGAATGGCATG   660
    Y  D  V  N  R  C  K  E  N  G  S  E  *

661 GCGACTTCATTTATGAAGGAAGACTTCCACAGATGTGAAACTTGCCTTCATTTTGCTTGT   720

721 TACTTTAGACCAACATATTCTTCCTTTTCCGACTTCAATGATATGATCTAGGTTGTAAAA   780

781 AGAGCGTTTTAATAAAGAAAGTATTAGCATCGATGATGGAAATATAAAAAAAA          832
```

Av-HBP

FIG. 6

```
   1  GCGACCGCGCCCAGCCGTACAGAACAAATAGCCTTCGTTGCAAACGTGCAGCGTAGTCGG   60

  61  ATGCCTAGTTAAACACCACACACACGTAAAAAGTAGACGAAACTGGCTTCGCTTCCAGCA  120

 121  CCAAGCAGGTCATCGTCTGGTCCACTGACGATGAACTCTGCCTTGTGGGTTTTACTAGGA  180
                                  M  N  S  A  L  W  V  L  L  G

 181  TCATCCTTATGGCTGCATACGGTAGCGTTCATGATTCCCACATGGGCAGATGAAGGCAGG  240
      S  S  L  W  L  H  T  V  A  F  M  I  P  T  W  A  D  E  G  R

 241  TTTGGCAAGTACCAGAACGCCTGGAAGGCCCTGAATCAGCGGATTAACACAACACATGTC  300
      F  G  K  Y  Q  N  A  W  K  A  L  N  Q  R  I  N  T  T  H  V

 301  CTTGTGAGGTCAACGTATATCGACAATCCATATTTATGGGGCAAGAACTTCTCATGCGTA  360
      L  V  R  S  T  Y  I  D  N  P  Y  L  W  G  K  N  F  S  C  V

 361  CGCGCTCGAACTGTCGAAGTCTTTCCCAGCAGCAAGACTGTGGAACTGGAGTTTAGTTTC  420
      R  A  R  T  V  E  V  F  P  S  S  K  T  V  E  L  E  F  S  F

 421  AGAAACAGGACTGGTATATTGTGCATGAGAAATCAAACGGTTCGAGCTGGAAAGGATTAC  480
      R  N  R  T  G  I  L  C  M  R  N  Q  T  V  R  A  G  K  D  Y


 481  TTTTATCATCAGCCTAACGCCTTCGAATTCATGCTGAGAGGTAACAGGTCGTTTTCTAAC  540
      F  Y  H  Q  P  N  A  F  E  F  M  L  R  G  N  R  S  F  S  N

 541  GCTGTCATGTTTACCGACGGAATGACATGTAATCTGCTCAGCTTTCCATACCAGCGCAAC  600
      A  V  M  F  T  D  G  M  T  C  N  L  L  S  F  P  Y  Q  R  N

 601  AAACCACAATGCGAACTATGGGTGAAGGACACGCGCGTCGACAACATTCCCCCTTGTTGC  660
      K  P  Q  C  E  L  W  V  K  D  T  R  V  D  N  I  P  P  C  C

 661  TCGTTCATGTTCGACTATTTGTGCCCACAGCCTCGTCCATTCATCATTTACGACAAAGCA  720
      S  F  M  F  D  Y  L  C  P  Q  P  R  P  F  I  I  Y  D  K  A
```

```
721  ATGTGCACGGTGAGGCCACCCCGCTAGAAAGAAAAGGGATGAAAAGGCTACTCGAAGAAG  780
     M  C  T  V  R  P  P  R  *

781  CAACAACCAATCAGTGCCCACAAGAGAACCGTTCCAGTCCTGCGAAAGTTGCGCCTCCCA  840

841  AAACACATACATTTCACTGCAAAGATGACCGATGCAGTCGCAAATTCGTGTCCTAGAACT  900

901  CAAGTGCTGTTTTGGAAACTCGGAAAGGAGACAGTAGAAGCTAACTGCTGTGATACCTAG  960

961  GCCAGGCATTTCCGTCGGGCACTGTTTTTTATGAATAGGGTAGGGTGAAAGTATTTTGGC  1020

1021 TTTGCTGTGGCCCAATAAATAGCGTATATTAGCGGACTAGCATCGAAGTTCCAGATGCTA  1080

1081 TAAAGCAGCTAAAACTCACTTCTGCCTGGAACTTCGATAGGTATTGAATAGATCATGCGC  1140

1141 GCACAGAAAAGAAAAGTATCAATCAAAACATAAAAAGCATTCTTCGCATGTGCGCAAAGC  1200

1201 ATTCCCTAAGTCCACGCTAAAAATAGGTGTCATTTCATATAGCATCGAGTTCTATACGTT  1260

1261 CTTAAGATGCTACCGGTCATTCATTCCTTTCTCGTCTATGCCTCATGGATCTGAACCAAG  1320

1321 TTCTTCTATTGCCTCCTTGTTTTCCGGTAGCTACAGAGTTCAGCAGCACCATTGCTAGTG  1380

1381 CATATTTTATCTTCGTGCTGTGTTTGTCGCAGTATATTTTTCTGCCTATTCACGATATTT  1440

1441 GCACAATGTAATAAAACATTTGCCTGCCTAAAAAAAAAAAAAAAAAAAA  1488
```

FIG. 6(contd.)

Ih/Bm-HBP1

FIG. 7

```
1   CTCCAGCTCTGCTTCGACGATGAAGGCTCTCCTGATCGCTGTCGGCTACCTGGCTGCCGT   60
                      M  K  A  L  L  I  A  V  G  Y  L  A  A  V

61  CACAGCGGCACCCCAAGCTTCGCCTTCCTCTCCGAGGAACGAACCACTCAAGAATACTAC  120
    T  A  A  P  Q  A  S  P  S  S  P  R  N  E  P  L  K  N  T  T

121 GTGGCACAGCAAGGAACTGAAAAATTATCAAGATGCGTGGAAGTCCATCAATCAAAACGT  180
    W  H  S  K  E  L  K  N  Y  Q  D  A  W  K  S  I  N  Q  N  V

181 CAGCACTACCTACTACTTCCTCAGATCAACCTACAACAACGACAGTGTCTGGGGTAAAAA  240
    S  T  T  Y  Y  F  L  R  S  T  Y  N  N  D  S  V  W  G  K  N

241 TTTCACCTGTCTTAGCGTCACGGTGACATCGAAACATGAATCAACGTTCACCGTCGAATA  300
    F  T  C  L  S  V  T  V  T  S  K  H  E  S  T  F  T  V  E  Y

301 TAACACCACGTACAAAAATCAGAGCCAACAATGGGTCAGCATGACGGAAAACGTCACGGC  360
    N  T  T  Y  K  N  Q  S  Q  Q  W  V  S  M  T  E  N  V  T  A

361 CGTGCAGGAGGAGGGCTACGACGTTAAAAATATCATTCAGTGGACAACAGAGAATAACAC  420
    V  Q  E  E  G  Y  D  V  K  N  I  I  Q  W  T  T  E  N  N  T

421 AAAGTTCAATGATACTGTTGTTTTTACGGACGGCCAGACTTGTGATCTGTTGTACATCCC  480
    K  F  N  D  T  V  V  F  T  D  G  Q  T  C  D  L  L  Y½ I  P

481 GTACAAAGAAAACGGTTACGAGCTGTGGGTGCGTTCGGATTACCTGCAGAACACTCCAAC  540
    Y  K  E  N  G  Y  E  L  W  V  R  S  D  Y  L  Q  N  T  P  T

541 GTGCTGCCAGTTCATCTTTGACCTCGTCGCATTGGGACGTACCACGTACAATATCTCCAC  600
    C  C  Q  F  I  F  D  L  V  A  L  G  R  T  T  Y  N  I  S  T

601 TCCTGACTGCGTGACCAAAACCTCTCGTTAGACCGTGAAAGCCGCGGCTTATGCTACTCG  660
    P  D  C  V  T  K  T  S  R  *

661 ACTGCTCAGGTTGGAAGAGTAGGGAGCCCCGACGCGCACTACTACTAAAAATGATTCCAA  720

721 ATAAAGTATTCAAACATTTCAAAAAAAAAAAAAAAAAAAA                      760
```

Ih/Bm-HBP2

FIG. 8

```
   1  AGTGACTCCTGCTCTGCTTCGACGATGAAGGCTCTCCTGATCGCTGTCGTCTACCTGACT   60
                              M  K  A  L  L  I  A  V  V  Y  L  T

  61  GCCGTCACAGCGGCAGACCAAGCTCCGCCTTCCTCTACGAGGAATGAACCACTCGAGAAA  120
      A  V  T  A  A  D  Q  A  P  P  S  S  T  R  N  E  P  L  E  K

 121  ACTACCTGGCACAACCAGACACTGGGACGTTATCAAGATGCGTGGAAGTCCATCAATCAA  180
      T  T  W  H  N  Q  T  L  G  R  Y  Q  D  A  W  K  S  I  N  Q

 181  AGCGTCGGCACTACCTACTACTTCCTCAGATCAACCTACAACAACGACAGCGTGTGGGGT  240
      S  V  G  T  T  Y  Y  F  L  R  S  T  Y  N  N  D  S  V  W  G

 241  AAAAATTTCACCTGTCTTAGCGTCACGGTGACATCGAAATATGAATCAACGTTCACCGTC  300
      K  N  F  T  C  L  S  V  T  V  T  S  K  Y  E  S  T  F  T  V

 301  GAATATAACACCACGTACAAAAATCAGAGCCAACAATGGGTCAGCATGTCGGAAAACGTC  360
      E  Y  N  T  T  Y  K  N  Q  S  Q  Q  W  V  S  M  S  E  N  V

 361  ACGGCCGTGCAGGAGGGCGGCTACAGTGTTAAAAACATCATTCAGTGGACAACGGAGAAT  420
      T  A  V  Q  E  G  G  Y  S  V  K  N  I  I  Q  W  T  T  E  N

 421  AACACAAAGTTCAATGATACTGTTGTTTTTACGGACGGCCAGACTTGTGATGTGTTATAC  480
      N  T  K  F  N  D  T  V  V  F  T  D  G  Q  T  C  D  V  L  Y

 481  ATCCCGTACAAAGAAGACGGTTACGAGCTGTGGGTGCGTTCGGAATACCTGCAGAACACT  540
      I  P  Y  K  E  D  G  Y  E  L  W  V  R  S  E  Y  L  Q  N  T

 541  CCAACGTGCTGCCAGTTCATCTTTGACCTCGTCGCATTGGGACGTACCACGTACAATATC  600
      P  T  C  C  Q  F  I  F  D  L  V  A  L  G  R  T  T  Y  N  I

 601  TCCACTCCTAACTGCGTGGCCACCACCGCTGGTTAGACAATGCAAGCCGCGGCTTAATTT  660
      S  T  P  N  C  V  A  T  T  A  G  *

 661  ACTCGACCGCTCAGGTTGGAAGTGCCGGGAGCCTCGACGGGCACTACTACTTAAAATGAT  720

 721  TTCGAATAAAGTATTCAAGCATTTCTGGAAAAAAAAAAAAAAAAA  765
```

Ih/Bm-HBP-3

```
1   GATGGCGCTCAGATTTGCACTTCTGCTGGCGTGCATCGTCACGGCATGTGGCTGGAGAAC   60
      M  A  L  R  F  A  L  L  L  A  C  I  V  T  A  C  G  W  R  T

61  ACGGATTCAAGAGAAAGGTCCCGAGAACAACCCTCTCATGAACACCCAACGTTTGGGAAA  120
      R  I  Q  E  K  G  P  E  N  N  P  L  M  N  T  Q  R  L  G  K

121 AATGCAAGACGCATGGAAGAGTCTGGAAAAGGCAACAAATCAGTCGTATGTCTTGGTGTT  180
      M  Q  D  A  W  K  S  L  E  K  A  T  N  Q  S  Y  V  L  V  F

181 CCGCTCAAGAAATCACGAACCAGAGATATCCTGCGTGTACGTGAGGGCTAGTAATATAAA  240
      R  S  R  N  H  E  P  E  I  S  C  V  Y  V  R  A  S  N  I  N

241 TAATGACACTAAAACTGCAACTTATACCAGAACATATTACAATATGACGGCAAACGCAAC  300
      N  D  T  K  T  A  T  Y  T  R  T  Y  Y  N  M  T  A  N  A  T

301 CATGACGGTGAATTATACTGCAAGAGCTCTGAAGCAAGTGGACTATGAGTCGGAAAATGT  360
      M  T  V  N  Y  T  A  R  A  L  K  Q  V  D  Y  E  S  E  N  V

361 CGTACGAGTAAACCTGACAGGTGGGGTCCCCAGCAACGATACAGTTCCTCTTGGAAGCTA  420
      V  R  V  N  L  T  G  G  V  P  S  N  D  T  V  P  L  G  S  Y

421 CGAATACGTCGAGTACGGTAATTACTCCTGCAATAGCTCATCGACACCCTTTTTGGATGC  480
      E  Y  V  E  Y  G  N  Y  S  C  N  S  S  S  T  P  F  L  D  A

481 TGTGCAAATGGCATCGCAAGGGCAATCCAGAGGGCCGGATATCGAAGGGCGCACATATCT  540
      V  Q  M  A  S  Q  G  Q  S  R  G  P  D  I  E  G  R  T  Y  L
```

FIG. 9

FIG. 9 (CONTD.)

```
541  AGACTTCTACGTCGTCTACAATCAACCATCGTGCAATGTCCTGAAGTCCCCGCTCCTGGG   600
       D  F  Y  V  V  Y  N  Q  P  S  C  N  V  L  K  S  P  L  L  G

601  AGGTGCTTGTGACTTTTGGGTGACAGAATCCGAGTTGCAAAAAGCACTAAATAAGACATC   660
       G  A  C  D  F  W  V  T  E  S  E  L  Q  K  A  L  N  K  T  S

661  AGAGAAGAAAAAAACAAAGCTAGAAGCGAGAGCAAGGAAAGCTGGAGGAGATTCCGATGA   720
       E  K  K  K  T  K  L  E  A  R  A  R  K  A  G  G  D  S  D  D

721  CCAGGGACCTGAACTGGAGGTCGTCTTCAAAAATCTGCCCCCTCCCTGCCGCGCAGCGTT   780
       Q  G  P  E  L  E  V  V  F  K  N  L  P  P  P  C  R  A  A  F

781  CATAACTTCCTGCGGCTATCCAACTTTTCTTATGTACAACAAGACCATCTGTAATCGAAC   840
       I  T  S  C  G  Y  P  T  F  L  M  Y  N  K  T  I  C  N  R  T

841  GGATTCTGCTGCGGTGTGAACGTCCCCTGCGAGCAAGTAGAACGTCCGTGAAGACAGCAG   900
       D  S  A  A  V  *

901  GAAGATAGTTGACTGTTTTGTTGGCGGAATGTGACTACTAGTCTGAATCATTAAAAAGAT   960

961  TCNGCTGACGGGTGTGGCGGGAACTTTTTTAAATGAAATTGGTCATACTTGTTGAAAGAC   1020

1021 AAAAATAAAACAATATGTTACTCCTC  1046
```

Ih/Bm-HBP4

FIG. 10

```
1   GGAAACCAGGATGGCGCTCAGATTTGCACTTCTGCTGGCGTGCATCGTCACGGCATGTGG   60
              M  A  L  R  F  A  L  L  L  A  C  I  V  T  A  C  G

61  CTGGAGAACACGGATTCAAGAGAAAGGTCCCGAGAACAACCCTCTCATGAACACCCAACG   120
    W  R  T  R  I  Q  E  K  G  P  E  N  N  P  L  M  N  T  Q  R

121 TTTGGGAAAAATGCAAGACGCATGGAAGAGTCTGGAAAAGGCAGCAAATCAGACGTATGT   180
    L  G  K  M  Q  D  A  W  K  S  L  E  K  A  A  N  Q  T  Y  V

181 CTTGGTGTTCCGCTCAAGAAATCACGAACCAGATATATCCTGCGTCTACGTGAGAGCTAG   240
    L  V  F  R  S  R  N  H  E  P  D  I  S  C  V  Y  V  R  A  S

241 TAATTTAGATAATGCAACTAAAACTGCAGATTATACCAGAACATATTACAATATGACGGC   300
    N  L  D  N  A  T  K  T  A  D  Y  T  R  T  Y  Y  N  M  T  A

301 AAAACAAAACGTGTCGGTAAATTATACTGCAAGAGCTCTGAAGCAAGTGGACTATGAGTC   360
    K  Q  N  V  S  V  N  Y  T  A  R  A  L  K  Q  V  D  Y  E  S

361 GGAAAATGTCGTACGAGTAAACCTGACAGGTGGGGTCCCCAGTAACGATACAGTTCCTCC   420
    E  N  V  V  R  V  N  L  T  G  G  V  P  S  N  D  T  V  P  P

421 TGGAAGCTTCGAATACGTCGAGTACGGTAATTACTCCTGCAATAGCTCATCGACACCCTT   480
    G  S  F  E  Y  V  E  Y  G  N  Y  S  C  N  S  S  S  T  P  F

481 TTTGGATGCTGTGCAAATGGCATCGCAAGGGCAATCCTGGGGGCCGGATGTCGAAGGGCG   540
    L  D  A  V  Q  M  A  S  Q  G  Q  S  W  G  P  D  V  E  G  R
```

```
541  CACATATCTAGATTTCTACGTCGTCTACAATCAACCGTCGTGCAATGTCCTGAAGTCCCC  600
       T  Y  L  D  F  Y  V  V  Y  N  Q  P  S  C  N  V  L  K  S  P

601  GCTCCTGGGAGGTGCTTGTGACTTCTGGGTGCCACAATCAGAGTTGGACAAGGTACTAAA  660
       L  L  G  G  A  C  D  F  W  V  P  Q  S  E  L  D  K  V  L  N

661  CAAAAAAGGAGATAAGAAAAAGCCAGCTAAGTCAAGCAGTCAAAATGGAGACGAAGGTTC  720
       K  K  G  D  K  K  K  P  A  K  S  S  S  Q  N  G  D  E  G  S

721  TGATGCCGAGCAACCTGAACTGGAGGCCATCTTTAAACATCTACCCCCTCCCTGCCGCGC  780
       D  A  E  Q  P  E  L  E  A  I  F  K  H  L  P  P  P  C  R  A

781  AGCGTTCATAACTTCCTGCGGCTATCCAAATTTTCTCATGTACAACAAGACGATCTGTAA  840
       A  F  I  T  S  C  G  Y  P  N  F  L  M  Y  N  K  T  I  C  N

841  TGCAGCGGGTCATGCTGCGAACTGAACGTCCTCTGCGAACGAGTAGAGCGTGCGTAAAAA  900
       A  A  G  H  A  A  N  *

901  CAACTGGTCTGAATCTTTTAAGAAATTCGGCAAAGTGCGGGTGGCGCGAACTTTTATCAA  960

961  ACTGGTCATACATGTGAAAGAAAAAAATAAAACAAAATGTGCATAAAAAAAAAAAAAAAA  1020

1021 AAAAA  1025
```

FIG. 10(contd.)

WO 99/27104

09/555296
PCT/GB98/03530

FIG. 11

Ih/Bm-HBP-5

```
1   CGAAGAGCAGGTACGATTCGAATCTTTGCAATGGACATTCGCAGCGCTGTTTTGTTCGCG   60
                                  M  D  I  R  S  A  V  L  F  A

61  TGCATCGTCTCGGCGTGTTGTGGCTTTTGGCGCTGGACAACACGGAGGGTAACTAAAAAG  120
    C  I  V  S  A  C  C  G  F  W  R  W  T  T  R  R  V  T  K  K

121 CCTGATAACAGCCCTCTGTTGAACAACCAACATCTTGGTCTTTTCCAGGACGCATGGAAG  180
    P  D  N  S  P  L  L  N  N  Q  H  L  G  L  F  Q  D  A  W  K

181 ACTATAGAAGAGACGTCCAATGATACGTATGTCCTGATGTTCCGCTCAAAACATTACGAC  240
    T  I  E  E  T  S  N  D  T  Y  V  L  M  F  R  S  K  H  Y  D

241 CACGAGAACAAGGCTAAATGTGTCTTCGTAACGGCAAATATTACTGACTCCCGGAACAAA  300
    H  E  N  K  A  K  C  V  F  V  T  A  N  I  T  D  S  R  N  K

301 ACTGCCAATTACACAATAACGTATTACGATACTACAACAAATACATCCAACAATTTTACA  360
    T  A  N  Y  T  I  T  Y  Y  D  T  T  T  N  T  S  N  N  F  T

361 ATCCCAGTGAGAGCTCTGAACCAAACTGACTACTCACTAGAAAATGTGATTCGAGCAAGC  420
    I  P  V  R  A  L  N  Q  T  D  Y  S  L  E  N  V  I  R  A  S

421 TTCAACGGCGACACTCCAAGCTCTACTCCAGCCCCTCCCGGAAGCAGCGTGTACATTCAG  480
    F  N  G  D  T  P  S  S  T  P  A  P  P  G  S  S  V  Y  I  Q

481 TATAATAATGTTACCTGCTACGCCCAATATCACCCATTTTCAAATAATGGAATCAGTGCA  540
    Y  N  N  V  T  C  Y  A  Q  Y  H  P  F  S  N  N  G  I  S  A
```

FIG. 11 (CONTD.)

```
541  AAATATGATGAAATGCCCCGGGATGGCCGAAATTACTTGTTCGACAATTTTATTGGTGCT  600
     K  Y  D  E  M  P  R  D  G  R  N  Y  L  F  D  N  F  I  G  A

601  TACTTGGACTTCTACGTGGTGTTCAGCCAGCCGACATGCAACGTTCTCAGAGTCCGAGAA  660
     Y  L  D  F  Y  V  V  F  S  Q  P  T  C  N  V  L  R  V  R  E

661  GGATGTGACTTCTGGCTAAGGAAAACTGAGTTGCCAAGCCTACTGAAAGCAGCAGAAAAT  720
     G  C  D  F  W  L  R  K  T  E  L  P  S  L  L  K  A  A  E  N

721  GATGACAACGATAACACGGAATCGCTGAAGAACTATTGGGAAAGAAGAATAAATAATACT  780
     D  D  N  D  N  T  E  S  L  K  N  Y  W  E  R  R  I  N  N  T

781  AAAACAAGATTTCGACATAATACTAAGAAATGTAAGATGTACGTACAACGTTATTCAATT  840
     K  T  R  F  R  H  N  T  K  K  C  K  M  Y  V  Q  R  Y  S  I

841  GAGAAGGCTGAAGATGTCTTTAAAAACACTGCTTTTAAACACCTCCCCTCCGACTGCCGC  900
     E  K  A  E  D  V  F  K  N  T  A  F  K  H  L  P  S  D  C  R

901  TTTGCCTTCCTGGCCGCTTGTGGAAATCCAGCATTCACAATATACGACCCAGAAACATGT  960
     F  A  F  L  A  A  C  G  N  P  A  F  T  I  Y  D  P  E  T  C

961  AATAGCTCCCTGCCAGCTAATATGGCAGAAAGTTAAATGAGCTATTTCACTTCATGTTCG  1020
     N  S  S  L  P  A  N  M  A  E  S  *

1021 ACCGTATGCCTGGTATGCAAGAAGGTGAGGTTGGACAGGATACTTCCGAATTATTTTTTC  1080

1081 AGTCTGCCTTGTACGCACGAAATAACAAAATATCTGTTGAAGCCNNCAACNNNNNNAANA  1140

1141 ANAAAAAANAAAAAAA 1156
```

09/555296



FIG. 12



FIG. 13



FIG. 14

FIG. 15

Binding Activity of derretine to histamine and its methylsubstitutions



FIG. 16


Histamine-binding saturation curve
[BOUND] nM
[Free histamine] nM
0
1
2
3
4
5
0
100
200
300
400
500
y = 0.7392Ln(x) + 0.1072
y = 0.4508Ln(x) + 0.6065
y = 0.4386Ln(x) + 0.696


Scatchard (without 5-HT)
y =0.5671e-0.8176x
[B]/[F]
0.5
0.4
0.3
0.2
0.1
0
0
2
4
6
[B] nM.

FIG. 17

FIG. 17(contd.)


Scatchard (+2.38nM 5-HT)
y=1.1021e-1.3619x
[B]/[F]
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0
1
2
3
4
[B] nM


Scatchard (+23.8nM 5-HT)
y=1.5254e-1.4632x
[B]/[F]
[B] nM.
0
0.2
0.4
0.6
0.8
1
0
1
2
3
4

FIG. 17(contd.)

FIG. 18

FIG. 19



FIG. 20(a)



FIG. 20(b)

FIG. 20(c)



FIG. 20(d)



FIG. 21(a)



FIG. 21(b)



FIG. 21(c)


Tyr 29
Ser
Asp 120
Wat
Asp 2
Wat 5
Leu 21
Val 51
Wat 4
Ile 122
Phe
Tyr 100
Tyr
Ser
Asp 120
Wat 5
Leu 21
Val 51
Wat 4
Ile 122
Phe
Tyr 100


ihhbp3
ihhbp4
ihhbp5
FS-HBP1
FS-HBP2
MS-HBP1
ihhbp1
ihhbp2
D.RET6
avhbp
ra-res

FIG. 22


ihhbp3 LDAV------QMASQGQSRGPDIEGRTYLDFYVVYNQPSCNVL----KSPLLGGAC 203
ihhbp4 LDAV------QMASQGQSWGPDVEGRTYLDFYVVYNQPSCNVL----KSPLLGGAC 203
ihhbp5 SNNGISAKYDEMPRDGRNYLFDNFIGAYLDFYVVFSQPTCNVL----R---VREGC 212
FS-HBP1 ----------------------GQVLTDVLAFSD-DNCYVIYALGPDGSGAG-Y 152
FS-HBP2 ----------------------GQVFTDVIAYSD-DNCDVIYVPGTDGNEEG-Y 153
MS-HBP1 ----------------------RTQTFEDVFVFSDYKNCDVIFVPKERGSDEGDY 153
ihhbp1 ----------------------NTKFNDTVVFTDGQTCDLLYIPYKEN--G--Y 160
ihhbp2 ----------------------NTKFNDTVVFTDGQTCDVLYIPYKED--G--Y 160
D.RET6 ----------------------GLNITDTLIFTDGELCDVFYVPNADQ--G--C 163
avhbp ----------------------NRSFSNAVMFTDGMTCNLLSFPYQRNKPQ--C 154
ra-res ----------------------VNSIGPVRSNSENPPERLTASQESAQRDC 164
ihhbp3 DFWVTESELQKAL----------NKTSEKKKTKLEARARKAG------ 235
ihhbp4 DFWVPQSELDKVL----------NKKGDKKKPA-KSSSQNGD------ 234
ihhbp5 DFWLRKTELPSLLKAAENDDNDNTESLKNYWERRINNTKTRFRHNTKKCKMYVQRY 268
FS-HBP1 ELWATD---------- 158
FS-HBP2 ELWTTD---------- 159
MS-HBP1 ELWVSEDK---------- 161
ihhbp1 ELWVRSDY---------- 168
ihhbp2 ELWVRSEY---------- 168
D.RET6 ELWVKKSH---------- 171
avhbp ELWVKDTR---------- 162
ra-res VLWVDHDEKATQ---------- 176
ihhbp3 GDSDDQGPELEVVFKNLPPPCRAAFITSCGYPTFLMYNKTICN---RTDSAAV 285
ihhbp4 EGSDAEQPELEAIFKHLPPPCRAAFITSCGYPNFLMYNKTICN---AAGHAAN 284
ihhbp5 SIEKAEDVFKNTAFKHLPSDCRFAFLAACGNPAFTIYDPETCNSSLPANMAES 321
FS-HBP1 ----------YTDVPASCLEKFNEYAAGLP--VRD-VYT-----SDCLPE 190
FS-HBP2 ----------YDNIPAANCLNKFNEYAVGRE--TRD-VFT-----SACL-E 190
MS-HBP1 ----------IDKIPDCCKFTMAYFAQQQEKTVRN-VYTDSSCKPAPAQN 200
ihhbp1 ----------LQNTPTCCQFIFD-LVA-LGRTTYN-ISTPDCVTKTSR-- 203
ihhbp2 ----------LQNTPTCCQFIFD-LVA-LGRTTYN-ISTPNCVATTAG-- 203
D.RET6 ----------YKHVPDYCTFVFNVFCA-KDRKTYD-IFNEECVYNGEPWL 209
avhbp ----------VDNIPPPCCSFMFDYLCP-QPRPF---IIYDKAMCTVRPPR 198
ra-res ----------EQCCEDFFKTHCKETVHVIYDVNRC-----KENGSE 207

FIG. 22(CONTD.)

Attorney Docket No.: 2369-1-002

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below under my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

HISTAMINE AND SEROTONIN BINDING MOLECULES

the Specification of which

[X] is attached hereto

[X] was filed on 26 November 1998
as International Application No. PCT/GB98/03530

I hereby state that I have reviewed and understand the contents of the above-identified Specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN FILED APPLICATION(S)			
APPLICATION NUMBER	COUNTRY	(MONTH/DAY/YYYY)	PRIORITY CLAIMED
9725046.8	**Great Britain**	**November 26, 1997**	**YES**
9813917.3	**Great Britain**	**June 26, 1998**	**YES**

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER(S)	FILING DATE (MM/DD/YYYY)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application No.	PCT Parent Number	Parent Filing (MM/DD/YYYY)	Parent Patent Number (if applicable)

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from **CARPMAELS & RANSFORD** as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

I hereby appoint as my attorneys or agents the registered persons identified under

Customer No. 23565

for the law firm of Klauber & Jackson, said attorneys or agents with full power of substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Please address all correspondence regarding this application to **Customer No. 23565**.

~~DAVID A. JACKSON, ESQ.~~
KLAUBER & JACKSON
411 HACKENSACK AVENUE
HACKENSACK, NEW JERSEY 07601

Direct all telephone calls to David A. Jackson at (201) 487-5800.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that

these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST JOINT INVENTOR: Patricia AnneNUTTALL

COUNTRY OF CITIZENSHIP: United Kingdom

FULL RESIDENCE ADDRESS:
1, Manor Farm
Culham
Oxon
OX14 4NP
United Kingdom

FULL POST OFFICE ADDRESS: SAME AS ABOVE

SIGNATURE OF INVENTOR _____

DATE 11/07/2000

FULL NAME OF SECOND JOINT INVENTOR: Guido Christiaan PAESEN

COUNTRY OF CITIZENSHIP: BELGIUM

FULL RESIDENCE ADDRESS:

Previous Address:	Present Address:
12, Mansfield Road	Guy Court,
Oxford	Flat 2,
OX1 3TA	1 King Street,
United Kingdom	Jericho,
	Oxford
	OX2 6DB
	United Kingdom

FULL POST OFFICE ADDRESS: SAME AS ABOVE

SIGNATURE OF INVENTOR _____

DATE 11/7/2000